Structural and Functional Characterization of Pattern Recognition Receptors of the Innate Immune System by Pippig, Diana Angela
Dissertation zur Erlangung des Doktorgrades 
der Fakultät für Chemie und Pharmazie 
der Ludwig-Maximilians-Universität München 
 
 
 
Structural and Functional Characterization 
of Pattern Recognition Receptors of the 
Innate Immune System 
 
 
Diana Angela Pippig 
aus 
Plauen 
 
 
München, 2010 
  
Erklärung 
 
Diese Dissertation wurde im Sinne von § 13 Abs. 3 bzw. 4 der Promotionsordnung 
vom 29. Januar 1998 von Herrn Prof. Dr. Karl-Peter Hopfner betreut. 
 
 
 
Ehrenwörtliche Versicherung 
 
Diese Dissertation wurde selbstständig, ohne unerlaubte Hilfsmittel erarbeitet. 
 
 
 
München, am 17.08.2010 
 
 
 
 
   ........................................... 
                  Diana Pippig 
 
 
 
 
 
Dissertation eingereicht am: 17.08.2010 
1. Gutachter:   Prof. Dr. Karl-Peter Hopfner 
2. Gutachter:    Prof. Dr. Elena Conti 
Mündliche Prüfung am:  19.10.2010 
  
This thesis has been prepared from February 2007 to August 2010 in the laboratory of 
Professor Dr. Karl-Peter Hopfner at the Gene Center of the Ludwig-Maximilians-University 
of Munich (LMU). 
 
 
 
Parts of this thesis have been published: 
 
Pippig, D. A., Hellmuth, J. C., Cui, S., Kirchhofer, A., Lammens, K., Lammens, A., Schmidt, 
A., Rothenfusser, S. and Hopfner, K. P. (2009). "The regulatory domain of the RIG-I family 
ATPase LGP2 senses double-stranded RNA." Nucleic Acids Res 37(6): 2014-2025. 
 
 
Parts of this thesis have been presented at the following international conferences: 
 
Posters displaying the “Structural and Functional Characterization of RIG-I Like Receptors” 
were presented at: 
 
RNA 2008: Thirteenth Annual Meeting of the RNA Society; Berlin, Germany, August 2008 
 
EMBO Conference Series: Helicases and NTP-Driven Nucleic Acid Motors – Structure,     
Function, Mechanism and Roles in Human Disease; Les Diablerets, Switzerland, June 2009 
   
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
„Dass ich erkenne, was die Welt im Innersten zusammenhält“  
Goethe, Faust I 
Table of Contents 
1. Introduction ........................................................................................................................... 1 
1.1. The Immune System .......................................................................................................... 1 
1.1.1. Surface Barriers as First Primitive Stage of Immune Defense ................................... 1 
1.1.2. Innate Immunity – The Second Stage .......................................................................... 2 
1.1.3. Adaptive Immunity – A Third Stage in Vertebrate Immunity ..................................... 3 
1.2. Pattern Recognition Receptors of the Innate Immune System .......................................... 4 
1.2.1. Nucleic Acid Responsive PRRs ................................................................................... 6 
1.2.2. PRR’s Knowing Friend from Foe ............................................................................... 8 
1.3. RIG-I-like Receptors ......................................................................................................... 9 
1.3.1. LGP2 – The Odd Member of the RLR Family .......................................................... 11 
1.3.2. RD – Regulatory or Repressor Domain? .................................................................. 11 
1.4. Inflammasomes – Stress and Infection Inducible Multi Protein Platforms .................... 14 
1.4.1. Types of Inflammasomes ........................................................................................... 14 
1.4.2. RLR Signaling and Inflammasomes – a Possible Intersection ................................. 16 
1.4.3. The AIM2 Inflammasome – a Cytosolic DNA sensor ............................................... 16 
1.4.4. AIM2 and the Interferon-Inducible p200 Protein Family ........................................ 17 
1.4.5. ASC – A Versatile Adaptor in Inflammation and Innate Immunity .......................... 19 
1.5. Objectives ....................................................................................................................... 21 
2. Material and Methods ......................................................................................................... 22 
2.1. Materials ......................................................................................................................... 22 
2.1.1. Chemicals.................................................................................................................. 22 
2.1.2. Media and Supplements ............................................................................................ 22 
2.1.3. Bacterial Strains ....................................................................................................... 23 
2.1.4. Plasmids .................................................................................................................... 23 
2.1.5. Cloning and Mutagenesis Primer ............................................................................. 24 
2.1.6. RNA and DNA Oligonucleotides .............................................................................. 25 
2.2. Methods .......................................................................................................................... 27 
2.2.1. Molecular Biological Methods ................................................................................. 27 
2.2.1.1. Molecular Cloning .............................................................................................. 27 
2.2.1.2. Site Directed Mutagenesis .................................................................................. 28 
2.2.1.3. Transformation ................................................................................................... 28 
2.2.1.4. Plasmid Preparation ........................................................................................... 28 
2.2.1.5. Bacmid Preparation ............................................................................................ 28 
2.2.2. Protein Biochemical Methods ................................................................................... 29 
2.2.2.1. Protein Expression in Insect Cells ...................................................................... 29 
2.2.2.2. Protein Expression in E.coli ............................................................................... 29 
Table of Contents 
2.2.2.3. Protein Purification ............................................................................................ 30 
2.2.2.3.1. Glutathione-S-Transferase Affinity Chromatography .................................. 30 
2.2.2.3.2. Nickel Affinity Chromatography ................................................................... 32 
2.2.2.3.3. Heparin Affinity Chromatography ................................................................ 32 
2.2.2.3.4. Dialysis .......................................................................................................... 32 
2.2.2.3.5. An- and Cation Exchange Chromatography ................................................. 32 
2.2.2.3.6. Size Exclusion Chromatography (SEC or Gelfiltration) ............................... 33 
2.2.3. Crystallographic Methods ........................................................................................ 33 
2.2.3.1. Crystallization ..................................................................................................... 33 
2.2.3.2. Crystallographic Data Collection of LGP2 RD .................................................. 34 
2.2.3.3. Structure Determination of LGP2 RD ................................................................ 34 
2.2.3.3.1. Theoretical Background ................................................................................ 34 
2.2.3.3.2. Solution of the LGP2 RD Structure ............................................................... 35 
2.2.4. RNA and DNA Biochemistry ..................................................................................... 36 
2.2.4.1. RNA Preparation ................................................................................................ 36 
2.2.4.2. Ribozymes and DNAzymes .................................................................................. 37 
2.2.5. Biochemical Assays................................................................................................... 37 
2.2.5.1. Fluorescence Anisotropy Measurements ............................................................ 37 
2.2.5.2. Electrophoretic Mobility Shift Assays ................................................................. 38 
2.2.5.3. Pulldown Assays ................................................................................................. 38 
2.2.5.4. Western Blots and Immunostaining .................................................................... 39 
2.2.6. Bioinformatic Methods ............................................................................................. 39 
2.2.6.1. Sequence Alignments .......................................................................................... 39 
2.2.6.2. Calculation of Protein Parameters ..................................................................... 39 
2.2.6.3. Structure Visualization and Analysis .................................................................. 39 
2.2.6.4. Protein Profile Search ........................................................................................ 40 
2.2.6.5. Structural Homology Modeling .......................................................................... 40 
2.2.6.6. Secondary Structure Predictions ........................................................................ 40 
2.2.7. Analytical Methods ................................................................................................... 40 
2.2.7.1. Mass Spectrometry .............................................................................................. 40 
2.2.7.2. Edman-Sequencing ............................................................................................. 40 
3. LGP2 – Results .................................................................................................................... 41 
3.1. Full Length LGP2 ........................................................................................................... 41 
3.2. The Regulatory Domain of LGP2 ................................................................................... 42 
3.2.1. Constructs and Purification ...................................................................................... 42 
3.2.2. Crystallization and Structure Determination of LGP2 RD ...................................... 43 
Table of Contents 
3.2.3. Overall Structure ...................................................................................................... 44 
3.2.4. Comparison of LGP2 RD to RIG-I and MDA5 RDs ................................................. 47 
3.2.5. LGP2 RD Binds to dsRNA in a 5’-Triphosphate Independent Manner .................... 50 
3.2.6. The dsRNA Binding Site of LGP2 ............................................................................. 52 
3.2.6.1. Study of LGP2 RD’s RNA Interaction by Fluorescence Anisotropy ................... 53 
3.2.6.2. Electrophoretic Mobility Shift Assays of LGP2 RD – RNA complexes .............. 54 
3.3. RD – RNA Complex Crystallization Attempts ................................................................ 55 
3.3.1. Generation of 5’-Triphosphate RNAs for Co-crystallization with RIG-I RD ........... 55 
3.3.2. Co-crystallization of RIG-I RD with 5’-Triphosphate RNA ..................................... 59 
4. AIM2 – Results .................................................................................................................... 61 
4.1. Full Length Mouse AIM2 ................................................................................................ 61 
4.1.1. Identification and Purification of Degradation Products of mAIM2 ....................... 61 
4.1.2. Structural Model of AIM2 ......................................................................................... 62 
4.2. The AIM2 HIN Domain .................................................................................................. 64 
4.3. Evaluation of mAIM2 – DNA Complex Formation by Electrophoretic Mobility Shift 
Assays .................................................................................................................................... 65 
4.4. Analytical Gelfiltration of Complexes of mAIM2 and DNA Ligands Suited for 
Crystallization ....................................................................................................................... 66 
4.5. Crystallization of AIM2 – dsDNA Complexes ................................................................ 67 
4.6. AIM2 and ASC Interaction ............................................................................................. 69 
5. Discussion ............................................................................................................................ 73 
5.1. RLR Regulatory Domains Have a Common RNA Binding Site ...................................... 73 
5.1.1. RLR RNA Binding Specificities are Determined by a Variable Loop Region in the 
RD ....................................................................................................................................... 75 
5.1.2. LGP2 RD Binds to dsRNA Ends ............................................................................... 75 
5.2. LGP2 as a Regulator of RIG-I and MDA5 Signaling ..................................................... 78 
5.3. Possible Mechanisms of LGP2 Interference with MDA5 and RIG-I Signaling ............. 80 
5.4. The AIM2 Inflammasome – Preliminary Functional Insights ........................................ 84 
5.4.1. Crystallization of AIM2 – DNA Complexes .............................................................. 86 
5.5. Comparison of RLRs and AIM2 ...................................................................................... 86 
6. Summary .............................................................................................................................. 88 
7. References ............................................................................................................................ 90 
Abbreviations 
Curriculum Vitae 
Acknowledgements
Introduction 
1 
 
1. Introduction 
1.1. The Immune System 
The immune system is a means of antagonizing pathogenic infection of and by an 
organism. It is, with varying complexity, present in all kingdoms of life. In higher developed 
organisms the immune system features a certain hierarchy of protection levels. Thereby the 
specificity of the defense reaction increases with the respective level reached by the pathogen 
attacking the host. Namely, these stages comprise first physical, chemical or biological 
surface barriers and secondly components of the so called innate immune system. Solely in 
jawed vertebrates a third, evolutionary younger, defense strategy has developed that is termed 
adaptive immunity. 
Major tasks of the vertebrate immune system comprise the chemoattractive recruitment 
of immunologically active cells to infection foci and the identification and neutralization of 
pathogenic substances by such specialized leukocytes. Further, the removal of infectious 
agents and infected cells, as well as the establishment of a memory function towards the 
respective antigen stimulus have to be prompted (Alberts et al. 2002).  
 
1.1.1. Surface Barriers as First Primitive Stage of Immune Defense 
Surface barriers are entirely non-specific and can be physical, such as plant cuticles, 
insect exoskeletons, skin and membranes that bound cells. Other mechanical defense 
mechanisms comprise physical removal of pathogens by peristalsis or cilia movement as well 
as coughing and sneezing to expel pathogens. Moreover, tears, saliva and urine have a 
flushing effect and mucosal excretion facilitates pathogen trapping.  
The latter mechanisms also include chemical barriers. Secretions commonly harbor anti-
microbial proteins or enzymes, like defensins, lysozyme, phospholipase and proteases or 
exhibit a low pH that is growth inhibitory towards pathogens (Alberts et al. 2002). 
Commensal bacteria represent a biological barrier by competing with other harmful 
bacteria for nutrients and space or by employing their own defense mechanisms by secreting 
toxins or altering the environmental pH.                 
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1.1.2. Innate Immunity – The Second Stage 
The second stage of the immune system is also inherited and exhibits very little 
specificity. This so called innate immunity is distinguished by an immediate and maximum 
effect triggered in response to pathogen invasion but does not feature any immune memory 
function.  
 The innate immune response is not directed against distinct pathogens but acts in a more 
generic way. It is activated by a broad range of common pathogen associated molecular 
patterns (PAMPs) and damage or danger associated molecular patterns (DAMPs) that arise 
from neighboring infected or damaged cells. The innate immune system comprises cellular as 
well as humoral, secreted extracellular components.  
Phagocytic leucocytes and macrophages represent a cellular barrier. They can sense and 
engulf foreign matter or microbes into endosomes. These are then fused to lysosomes that 
harbor various enzymes, like lysozyme and proteases or reactive oxygen species (ROS) 
allowing for the disintegration of the pathogenic components. Cells of the innate immune 
system are also involved in prompting inflammation and antigen presentation to components 
of the specific adaptive immune system by major histocompatibility complexes (MHC) on 
their surface (Alberts et al. 2002).  
Humoral components in innate immunity comprise the complement system and various 
pro-inflammatory or antiviral cytokines, such as interferons (INFs) and interleukins (ILs). 
Complement is a complex network of constitutively present plasma and membrane-associated 
serum proteins which induce an inflammatory and cytolytic reaction towards pathogens or 
damaged tissue when activated. It is implied in chemotactic attraction of phagocytic cells, 
membrane rupture of foreign or infected cells, opsonization and clearance of neutralized 
antigen-antibody complexes. Complement thereby bridges the innate and acquired immune 
system branches (Dunkelberger et al. 2010). 
Cytokines are messenger molecules and a variety of cytokine receptors, either membrane 
associated or cytosolic, are known. Examples are Type I and II cytokine receptors, seven 
transmembrane helix/G-Protein coupled receptors and the Tumor Necrosis Factor Receptor 
(TNFR) family. Defects in these receptors give rise to immunodeficiency. Cytokines that are 
upregulated by the innate immune system act either as active inhibitor of for instance viral 
replication (INF) or passively by facilitating chemotaxis (chemokines). Interleukins also drive 
the proliferation and differentiation of T-, B- and hematopoietic cells or induce fever and the 
upregulation of acute phase proteins (ferritin, C reactive protein, complement factors etc.) as 
well as further cytokines as inflammatory response. 
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Apart from these small effector molecules, the main molecular players in innate 
immunity are germline encoded pattern recognition receptors (PRRs) that specifically target 
PAMPs. These can be viral or bacterial nucleic acids, cell wall components or microbial 
toxins that are either sensed by cell surface located receptors or after entering the cell by 
cytosolic PRRs. Furthermore DAMPs that arise from damaged, stressed or infected cells are 
recognized by receptors of the innate immune system. Upon sensing of pathogenic patterns, 
PRRs trigger a signal transduction cascade that leads to the production and upregulation of the 
previously mentioned humoral, pro-inflammatory molecules (Chaplin 2010). 
 
1.1.3. Adaptive Immunity – A Third Stage in Vertebrate Immunity 
If the first two immune system barriers are evaded by the pathogen, a third stage is 
activated in vertebrates. This immune response is termed adaptive or acquired because it 
specifically acts on certain pathogens or antigens and due to its enabling immunological 
memory processes. The adaptive system requires first activation by the innate immune 
response and therefore initially exhibits a lag time between pathogen infection and the 
ultimate reaction. In case of recurring presentation with an already known stimulant the effect 
is however faster, increasing and extremely efficient. 
Key players in adaptive immunity are T- and B-cells, two classes of specialized 
lymphocytes. They harbor a particularly diverse repertoire of antigen-specific recognition 
receptors and ensure specific identification and elimination of pathogens. Furthermore, they 
facilitate adaptive immune measures that enable tailored immune responses and long-lived 
memory against reinfection (Dunkelberger et al. 2010).  
As opposed to the germline encoded PRRs of the innate immune response, the antigen-
specific receptors of the adaptive system gain their diversity through somatic rearrangement 
of gene building blocks to form intact T-cell receptor (TCR) and immunoglobulin (B-cell 
antigen receptor) genes. This mode of receptor assembly from a collection of hundreds of 
germline-encoded gene elements in turn allows for the formation of millions of different 
antigen receptors and ensures unique specificity for a vast variety of antigens (Bonilla et al. 
2010; Chaplin 2010). While T-cell receptors sense antigens only in a processed form 
presented by MHCs, B-cells harbor receptors that recognize raw antigens. These receptors are 
cell membrane standing immunoglobulins. Such antibodies also occur as humoral, secreted 
components of the adaptive immune system. They mainly originate from B-cell derived 
plasma cells and are also directed against specific antigens. Antibody-antigen complex 
formation favors phagocytic activity and complement activation. The immunological memory 
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effect is thereby guaranteed by a fraction of the antibody producing cells that remain as 
persistent memory B-cells (Tangye et al. 2009; Chaplin 2010). 
 
1.2. Pattern Recognition Receptors of the Innate Immune System 
Defending the body against intruding pathogens is an intricate undertaking that requires 
interplay between the innate and adaptive immune systems and unambiguous distinction 
between pathogenic and intrinsic patterns. The innate immune system resembles a second line 
of defense against pathogen infection. It exhibits a broad specificity towards a wide range of 
germline-encoded pathogen-associated molecular patterns (PAMPs), like microbial RNA, 
DNA or cell wall components that can be encountered by the host-cell. PAMP detection is 
mediated by various inherited pattern recognition receptors (PRRs).  
PRRs trigger intracellular signaling cascades that lead to transcriptional upregulation and 
hence amplified expression of inflammatory mediators to coordinate the abolition of 
pathogens and infected cells. Importantly, deviant activation of PRR pathways can cause 
immunodeficiency, septic shock, or induction of autoimmunity. Thus, tight regulation is 
required (Takeuchi et al. 2010). 
Generally, activation of PRR signaling pathways triggers the nuclear translocation of 
various transcription factors, including NF-κB, AP-1, IRFs, and C/EBPβ. This leads to the 
production of pro-inflammatory, chemoattractive and anti-microbial cytokines by cooperative 
upregulation of the transcription of their target genes. Activation of some PRRs results in 
their processing of precursor pro-interleukins to mature active forms.  
Most PRRs are themselves IFN-inducible, allowing for an extremely robust innate 
immune response by positive feedback regulation. PRRs include endosomal membrane and 
cell surface located Toll-Like Receptors (TLRs) and C-type Lectin Receptors (CLRs) as well 
as intracellular Nucleotide-binding and Oligomerization Domain (NOD)-Like Receptors 
(NLRs). Further, Retinoid acid-Inducible Gene I (RIG-I)-Like Receptors (RLRs) and other, 
not yet grouped receptors like the cytosolic nucleic acid sensors AIM2 (Absent In Melanoma 
2) and DAI (DNA-dependent Activator of INF Regulatory Factors) have also been described. 
An overview of various PRRs is given in Table 1. 
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Table 1 Overview of PRRs, their cellular localization, ligands and the response they 
trigger; adapted from (Takeuchi et al. 2010) 
PRR Localization Ligand Origin of Ligand Response 
TLR     
TLR1 Membrane Triacyl lipoprotein Bacteria Cytokine production 
TLR2 Membrane Lipoprotein Bacteria, viruses, parasites, self Cytokine production 
TLR3 Endolysosome dsRNA Virus INF/Cytokine production 
TLR4 Membrane LPS Bacteria, viruses, self Cytokine production 
TLR5 Membrane Flagellin Bacteria B/T-cell differentiation 
TLR6 Membrane Diacyl lipoprotein Bacteria, viruses Cytokine production 
TLR7 (hsTLR8) Endolysosome ssRNA Viruses, bacteria, self INF/Cytokine production 
TLR9 Endolysosome CpG-DNA Viruses, bacteria,  protozoa, self INF/Cytokine production 
TLR10 Endolysosome Unknown Unknown Cytokine production 
TLR11 Membrane Profilin-like molecule Protozoa Cytokine production 
RLR     
RIG-I Cytoplasm 5'triphosphate dsRNA RNA viruses, DNA viruses INF/Cytokine production 
MDA5 Cytoplasm Long dsRNA RNA viruses INF/Cytokine production 
LGP2 Cytoplasm Unknown RNA viruses Regulator of RIG-I/MDA5 
NLR     
NOD1 Cytoplasm iE-DAP Bacteria Cytokine production 
NOD2 Cytoplasm MDP Bacteria Cytokine production 
CLR     
Dectin-1 Membrane ß-Glucan Fungi Cytokine production/TLR complex inhibition 
Dectin-2 Membrane ß-Glucan Fungi Cytokine production/TLR complex inhibition 
MR Membrane Mannose, Glucose,  N-Acetylglucosamin Bacteria, Fungi Cytokine production 
MINCLE Membrane SAP130 Self, fungi Cytokine production/TLR complex inhibition 
Inflammasomes    
NLRP1 Cytoplasm Toxins, LPS, MDP, crystals, ATP Bacteria, endogenous DAMPs IL-1β/18 maturation 
NLRP3 Cytoplasm Cathepsin, ROS, ATP, crystals Bacteria, endogenous DAMPs IL-1β/18 maturation 
NLRC4/ 
IPAF Cytoplasm Flagellin Bacteria IL-1β/18 maturation 
NAIP5 Cytoplasm Flagellin Bacteria IL-1β/18 maturation 
AIM2 Cytoplasm dsDNA Bacteria,  DNA viruses IL-1β/18 maturation 
others     
DAI Cytoplasm dsDNA Bacteria, DNA viruses INF/Cytokine production 
HMGB1 Cytoplasm dsDNA Bacteria, DNA viruses Activation of other PRRs 
RNA Pol III Cytoplasm dsDNA Bacteria, DNA viruses RLR activation by RNA transcripts 
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1.2.1. Nucleic Acid Responsive PRRs 
Viral and pathogen derived RNA is either recognized by Toll-like receptors or by RIG-I-
like Receptors or Helicases (RLR or RLH). The latter are a group of cytosolic superfamily 2 
(SF2) helicases comprising RIG-I, Melanoma Differentiation Associated protein 5 (MDA5) 
and Laboratory of Genetics and Physiology 2 (LGP2) (Kumagai et al. 2010). RLRs are 
ubiquitously expressed and even found in cells primarily involved in adaptive immunity (Kato 
et al. 2005). 
On the other hand, the presence of foreign DNA in the cytosol has been shown to be 
sensed by DAI (Takaoka et al. 2007) and indirectly by NLRP3 (NOD-Like Receptor family, 
Pyrin domain containing 3) (Muruve et al. 2008). Recently, the IFN-inducible protein AIM2 
has been also implicated in pathogenic DNA sensing in the cytosol. It has been shown to form 
a multimeric inflammasome complex upon DNA binding and by recruiting ASC (Apoptosis-
associated Speck-like protein containing a CARD; also PYCARD) and caspase-1 
(Burckstummer et al. 2009; Fernandes-Alnemri et al. 2009; Hornung et al. 2009; Roberts et 
al. 2009; Vilaysane et al. 2009).  
Moreover, another pathogenic DNA recognition mechanism has been revealed to link to 
RLR signaling. RNA Polymerase III has been shown to produce DNA derived RNA 
intermediates that can be sensed by RIG-I in the cytosol inducing type I interferon production 
(Ablasser et al. 2009; Chiu et al. 2009).  
The existence of PRRs and pathways responsive to exogenous or abnormal DNA has not 
been known for long and it is assumed that yet more remain to be discovered.  
Most of the so far described PRRs are cell-type or ligand specific. The group of High 
Mobility Group Box (HMGB) proteins is more versatile. Originally, they had been known to 
be nuclear proteins regulating chromatin structure and transcription. Only recently they have 
been implicated in nucleic acid delivery to PRRs for detection, by acting as more universal 
receptors (Yanai et al. 2009). A schematic overview of some of the pathways of innate 
immunity directed against pathogenic nucleic acids is depicted in Figure 1. 
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Figure 1  Schematic overview of some signaling pathways of the innate immune system directed against pathogenic nucleic acids with focus on 
the AIM2 inflammasome and RLR LGP2 as a regulator of RIG-I and MDA5 signaling (C = CARD). 
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1.2.2. PRR’s Knowing Friend from Foe 
PRRs stand at the beginning of a tightly regulated signaling network that ultimately 
triggers an antiviral or inflammatory response. Therefore discrimination between pathogenic 
or commensal organisms, as well as patterns occurring in the host cell itself is required. 
Commonly, important decisions also rely on two or more signals that are often further fine 
tuned by subtle thresholds for full activation of inflammatory effects and immunologically 
active cells.  
An example of such a proofreading mechanism is that in a first instance only the 
expression of intracellular pro-inflammatory precursors (e.g. pro-IL-1β and pro-IL-18) is 
stimulated upon PAMP recognition by PRRs. Maturation and secretion of inflammatory 
cytokines and hence pro-inflammatory signaling, can however be only achieved by 
recognition of a second “danger signal” or damage-associated molecular pattern (DAMP) in 
the cell. Such trigger inflammasome assembly (molecular multi protein platforms often 
containing NLRs or for example AIM2 and ASC as an adaptor molecule) and subsequent 
activation of caspase-1 that is required for the processing and release of inflammatory 
mediators, such as IL-1β and IL-18. DAMPs that induce inflammasome formation can be 
PAMPs that are present in the cytosol, like pathogenic DNA. Further, host-cell signaling 
molecules that have been released by other cells suffering from stress or infection, such as 
reactive oxygen species (ROS) or uric acid crystals (Gallucci et al. 2001) act in a similar way.  
Other PRRs, like RLRs, do not seem to have any “false bottom” mechanism. They can 
directly trigger interferon and cytokine production upon sensing pathogenic RNA in the 
cytosol. So the need for a different regulatory strategy arises in those pathways. This also 
gives rise to an important, if not the most crucial, question. How can PRRs and particularly 
RLRs discriminate between foreign and self patterns to, on one hand, act as extremely 
sensitive detectors for infection but at the same time prevent auto-immune reactions?  
Generally, the mere presence of certain nucleic acid species in the cytosol is enough to 
trigger an immune response. Yet, it is particularly important to gain detailed understanding of 
what the specifically sensed patterns of each receptor are and to characterize the respective 
pattern receptor interaction on a molecular base (Abdul-Sater et al. 2009; Stutz et al. 2009; 
Latz 2010). 
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1.3. RIG-I-like Receptors 
RLRs share a unique domain structure, consisting of a SF2 type DECH-box ATPase 
domain, a C-terminal regulatory domain (RD) and two N-terminal caspase activation and 
recruitment domains (CARDs). The latter are only found in RIG-I and MDA5, not LGP2 
(Fig. 2). In addition DICER, an RNase III family member that cleaves dsRNA as well as 
eIF4A, that is involved in splicing, ribosome biogenesis and translation have been grouped 
with the other RLRs due to the high conservation of their DExD/H and HELICc (C-terminal 
helicase domain) motives. However, despite their common ability to bind RNA no functional 
relation is apparent.  
 
 
 
 
 
 
Figure 2  Domain architecture of RIG-I like Receptors. 
 
Upon recognition of cytosolic pathogenic or pathogen-derived RNA, RIG-I and MDA5 
interact with the mitochondrial membrane associated adaptor IPS-1 (Interferon-β Promoter 
Stimulatory protein 1; also MAVS, CARDIF and VISA) via a homotypic CARD domain 
interaction. This initiates downstream signaling and an antiviral response by interferon and 
cytokine production is triggered (Kawai et al., 2005; Meylan et al., 2005). LGP2, lacking this 
direct downstream interaction, is a regulator in this pathway (Yoneyama et al. 2005). 
It has been shown, that unanchored poly-ubiquitin chains are required for CARD 
interaction of RIG-I and IPS-1 and therefore downstream signaling (Zeng et al. 2010). Upon 
RNA interaction RIG-I is understood to undergo a conformational change releasing the 
CARD domains from an auto-inhibitory state to allow for self-association and thus 
downstream signaling by interaction with IPS-1 (Cui et al. 2008). It has been speculated that 
the RD keeps the CARDs locked and hence RIG-I in a monomeric inactive form until it binds 
to specific RNA structures like 5’-triphosphates. Furthermore, LGP2’s RD has been 
suggested to bind to RIG-I CARDs in the same manner representing a trans-inhibitory 
mechanism. For this reason RD has formerly also been termed Repressor Domain rather than 
Regulatory Domain (Saito et al. 2007). 
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Various RNA virus classes are known to be sensed by RIG-I (e.g. Rhabdo-, Paramyxo-, 
Orthomyxo-, Filo-, Flavi- and Reoviruses), while MDA5 so far is only understood to also 
sense Flavi- and Reoviruses and exclusively Picornaviruses (Kato et al. 2006; Loo et al. 
2008).  
The major PAMP recognized by RIG-I has been found to be 5’-triphosphate on viral 
RNAs. This modification arises from RNA synthesis by many viruses and is typically not 
found on normally capped, dephosphorylated or processed endogenous RNA molecules 
(Hornung et al. 2006). Further RIG-I stimulating species are dsRNA, 3’- and 5’-
monophosphates of dsRNA, poly-U/UC rich regions in the Hepatitis C virus (HCV) genome 
and the synthetic dsRNA mimic polyinosine-polycytidylic acid (poly(I:C)). In addition, 
RNA Pol III transcribed 5’-triphosphate RNAs originating from microbial DNA entering the 
cell and antiviral 2’-5’ oligoadenylate activated RNaseL generated small dsRNAs activate 
RIG-I. The latter can also arise from self-RNA in order to amplify the immune response to 
another stimulus (Yoneyama et al. 2004; Yoneyama et al. 2005; Malathi et al. 2007; Saito et 
al. 2008a; Saito et al. 2008b; Takahasi et al. 2008; Ablasser et al. 2009; Chiu et al. 2009). 
Ligand specificity for MDA5 is less well understood. It has been suggested that it recognizes 
higher order RNA structures and rather long dsRNA strands, while RIG-I senses shorter ones. 
An extremely potent MDA5 stimulus is poly(I:C) (Kato et al. 2006; Kato et al. 2008; 
Pichlmair et al. 2009). 
LGP2 has initially been shown to bind Hepatitis C virus (HCV) RNA and Poly(I:C). The 
latter occurs with much higher affinity than for RIG-I and MDA5, despite the lack of a direct 
signaling ability of LGP2 (Yoneyama et al. 2005; Saito et al. 2007). Moreover, secondarily 
structured RNA and dsRNA have been introduced as possible LGP2 ligands (Rothenfusser et 
al. 2005). Still, little is known about the nature of the physiological ligand and its role in RIG-
I/MDA5 regulation by LGP2. 
Recently, another RIG-I signaling pathway has been discovered. 5’-triphosphate RNA 
exposed RIG-I, but not MDA5, has been shown to interact with the adaptor ASC to trigger 
caspase-1-dependent inflammasome activation and thus IL-1β production by a mechanism 
independent of IPS-1 or NLRPs (NLR containing a Pyrin domain). However, this interaction 
could not be shown in vitro and other binding partners might be required (Poeck et al. 2010). 
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1.3.1. LGP2 – The Odd Member of the RLR Family 
LGP2 stands out in the group of RLRs. Despite its lack of the N-terminal CARD or any 
other signaling domains, with the conserved helicase domain and RD it still harbors the 
entities that justify its being termed receptor. The high resemblance of these domains to RIG-I 
and MDA5 together with the missing signaling link gave early rise to speculations that LGP2 
is a regulator or even inhibitor of RLR signaling (Rothenfusser et al. 2005; Yoneyama et al. 
2005). 
LGP2 remains relatively uncharacterized. It has been shown to interact with dsRNA and 
in vivo studies revealed a repressing effect of LGP2 on RIG-I but not MDA5. The impact of 
LGP2 on RIG-I signaling has thereby been assigned to a possible RNA sequestration 
mechanism (Rothenfusser et al. 2005; Komuro et al. 2006; Saito et al. 2007).  
On the other hand, LGP2 has been shown to interfere with the RIG-I signaling pathway 
yet on another, RNA independent level. Immunoprecipitation assays revealed an interaction 
of LGP2 with IPS-1 in the C-terminal region, spanning residues 300-540, that include the 
IPS-1 mitochondrial transmembrane domain. It therefore competes with the downstream 
mediator kinase IKKε that shares the same interaction site. Importantly, a CARD-lacking 
RIG-I construct that might have functioned as LGP2 mimic did not behave comparably in this 
study. Moreover, no binding of LGP2 to the IPS-1 CARD was observed, correlating with the 
finding that LGP2 and CARD-mediated RIG-I binding to IPS-1 are not exclusive (Komuro et 
al. 2006). 
 
1.3.2. RD – Regulatory or Repressor Domain? 
The way viral RNA is specifically sensed and distinguished from abundant cellular RNA 
is not entirely understood. It has however been shown, that RNAs harboring a 5’-triphosphate, 
a modification arising from unprocessed viral RNA transcripts, are capable of activating 
ATPase activity in vitro and stimulate in vivo signaling of RIG-I (Cui et al., 2008; Hornung et 
al., 2006). This crucial interaction, even though it is likely to be only a part of the whole RNA 
sensing mechanism, has been assigned to the C-terminal (RD) domain of RIG-I.  
The C-terminal domains of RIG-I and LGP2 were initially referred to as Repressor 
Domains, after finding that RIG-I constructs lacking this domain confer constitutive signaling 
to the interferon-β promoter, while expression of only the C-terminal domain was inhibitory. 
This was also shown for LGP2 RD acting in trans to RIG-I (Saito et al. 2007; Vitour et al. 
2007). Recent results suggest a more regulatory function of RD rendering it to be a 
Introduction 
12 
 
Regulatory Domain. More insight into the crucial role of the C-terminal domain in 
nucleic acid binding and ligand specificity has been gained. Also RD became understood to 
target RLRs towards pathogenic RNA in the first place (Hornung et al. 2006; Pichlmair et al. 
2006; Cui et al. 2008). 
The crystal structure of the RIG-I RD (Fig. 3 A) (Cui et al. 2008) is related to eukaryotic 
GDP/GTP exchange factors of Rab-like small GTPases, e.g. MSS4 (PDB: 1HXR, 19% 
identity) and to Methionine sulfoxide reductase B from the bacterium Xanthomonas 
campestris (PDB: 3HCJ, 16% identity). A functional relationship is nevertheless very 
unlikely, given that the sequence identity for the structural analogs is insignificant. 
Furthermore, the relative number of positively charged residues, a prerequisite for RNA 
binding, is extremely small compared to RIG-I RD. However, a prominent shared feature is a 
Zinc coordination site, formed by four invariant cysteine residues, which is crucial for protein 
integrity and hence in vivo signaling of RIG-I (Fig. 3 B, C).  
 
Figure 3  (A) RIG-I RD in cartoon representation with electrostatic surface charge 
potential (blue -8 kT to red +8 kT). (B) Superposition of RIG-I RD (green) with the two 
structurally related proteins nucleotide exchange factor MSS4 (1HXR, pale blue) and MsrB 
(3HCJ, pale orange) (Zhu et al. 2001; Ranaivoson et al. 2009). (C) Conserved Zn2+ 
coordination fold. 
 
The RIG-I RD structure reveals an accessible, positively charged cleft that appears to be 
well suited to interact with the 5’-triphosphate ligand and RNA backbone phosphates (Fig. 
3 A). Despite the generally high similarity of RLR RDs, several residues, shown to be crucial 
for 5'-triphosphate dependent binding of RNA in RIG-I RD, vary amongst the other two RLR 
RDs. This likely confers their prevalent selectivity against different RNA molecules (Fig. 4).  
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An early working model for RIG-I was based on the assumption, that upon binding of 
RNA to the RD a conformational change in the whole molecule is triggered. This would shift 
the N-terminal CARDs into a more accessible conformation to enable interaction with 
CARDs of downstream signaling partners (Cui et al. 2008). The role of the RD in LGP2 
however is not as clear, as is the question as to whether the LGP2 mediated inhibition of 
RIG-I is due to a direct interaction, or competition for viral RNA.  
 
 
Figure 4  Multiple sequence alignment of human RLR RDs. Conserved cysteines 
forming the Zn2+ coordination site are marked with asterisks, identical residues are depicted in 
white and shaded with red, homolog residues are shown in red. 
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1.4. Inflammasomes – Stress and Infection Inducible Multi Protein Platforms 
Inflammation is the coordinated immune response to harmful stimuli that occur due to 
infections or tissue damage. While it is essential for host resistance to infections, 
inflammation can be detrimental when produced chronically or in excess and is therefore 
linked to various diseases. Most notably auto-immune diseases, auto-inflammatory disorders, 
cancer and septic shock can result from mal-function of the inflammatory immune response. 
Hence, a tight regulation of inflammatory processes is indispensable (Ferrero-Miliani et al. 
2007; Barton 2008).  
In response to injurious or infectious agents caspase-1 activating cytosolic 
multimolecular protein complexes, termed inflammasomes, are formed (Martinon et al. 
2002). In contrast to RLRs, inflammasomes function only in part in the transcriptional 
upregulation of immune response genes, but more importantly activate the cysteine protease 
caspase-1. The latter drives the maturation and secretion of pro-inflammatory interleukins of 
the IL-1 superfamily from precursors. These pro-ILs are expressed in response to other, 
primary PRR signaling pathways, like the RLR one. Secreted ILs are sensed by specific 
surface receptors on other cells.  
Inflammasomes are part of the inherited immune system. They act to bridge it to the 
adaptive one by producing the interleukins required for stimulating B- and T-cell 
differentiation and antigen specific receptor production. This effect is utilized in vaccination. 
A commonly used adjuvant in vaccines is aluminium hydroxide, which is capable of antigen 
adsorption. Aluminium hydroxide activates a specific inflammasome (Hornung et al. 2008). 
The so induced IL release and therefore triggering of an adaptive immune response is specific 
to the introduced antigen, extremely safe and effective (Eisenbarth et al. 2008). Furthermore, 
inflammasome mediated IL release causes fever and increased acute phase protein production.  
 
1.4.1. Types of Inflammasomes 
A key player in inflammasome assembly is the adaptor protein Apoptosis-associated 
Speck-like protein containing a CARD (ASC). It is also termed PYCARD due to it consisting 
of an N-terminal Pyrin (also DAPIN: Domain in APoptosis and INF response) and a 
C-terminal CARD domain. ASC is a common interaction partner in the inflammasome 
scaffold and usually indispensible for caspase-1 recruitment to this pro-inflammatory 
platform.  
Introduction 
15 
 
Despite the presence of ASC as a common adaptor, different types of inflammasomes 
can be distinguished (Fig. 5). A large group is made up by NOD-Like Receptor (NLR) 
inflammasomes. They exhibit a common domain structure usually containing a Leucine Rich 
Repeat (LRR), typically representing the receptor domain and a Nucleotide Binding (NBD) or 
NACHT (NAIP, CIITA, HET-E, TP1) domain that facilitates oligomerization upon ligand 
interaction. The NLR inflammasomes can be further differentiated. The NLRP (also NALP) 
inflammasomes additionally harbor a Pyrin domain (PYD) for ASC interaction and NLRC 
(also IPAF) inflammasomes lack PYD but instead contain a CARD domain for direct 
interaction with caspase-1. Nevertheless it has been suggested that signaling by the IPAF 
inflammasome is not entirely independent of ASC (Suzuki et al. 2007). Another NLR 
inflammasome is NAIP5 (also NLRB) that contains Baculoviral Inhibitor of apoptosis 
proteins Repeat (BIR) domain repeats instead of PYD or CARD and functions in 
collaboration with IPAF (Stutz et al. 2009; Schroder et al. 2010a). 
Figure 5  Overview of the assembly, domain structure and direct or indirect stimuli of 
different inflammasomes. 
 
It has been shown that inflammasomes are formed by oligomeric complexes of their 
building blocks; however exact stoichiometries are not known for most inflammasomes. For 
NLRP1 penta- and heptameric assemblies have been revealed by electron microscopy 
(Faustin et al. 2007). This work suggests a donut-shaped structure for inflammasomes similar 
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to the structure of the human apoptosome formed by a heptameric assembly of its CARD and 
NOD domains (Yu et al. 2005). 
The recently discovered AIM2 inflammasome is exceptional. It is the only so far known 
inflammasome that is specifically activated in direct response to cytosolic DNA. It further 
represents the first example of a non-NLR family member forming an inflammasome 
scaffold. The usual NLR motives are replaced by a C-terminal HIN-200 domain in AIM2. 
This part acts as a receptor of cytosolic dsDNA and is thought to confer oligomerization. 
AIM2 further harbors an N-terminal PYD for interaction with ASC (Burckstummer et al. 
2009; Fernandes-Alnemri et al. 2009; Hornung et al. 2009).  
In addition, the triggering of AIM2 inflammasome assembly through only one specific 
stimulus (dsDNA), while NLRP1 and NLRP3 are activated by various PAMPs and DAMPs, 
is unusual. The mechanism underlying this versatility in NLRP inflammasomes is not well 
understood. Evidence has arisen however, that NLRPs do not directly bind those diverse 
pathogenic molecules. They respond to a more unique secondary signal induced by primary 
PAMPs or a versatile adaptor capable of binding such (Schroder et al. 2010b; Tschopp et al. 
2010).  
 
1.4.2. RLR Signaling and Inflammasomes – a Possible Intersection 
Recently RIG-I has been found to also interact with ASC upon binding to viral RNA. 
Therefore, it is potentially capable of forming an IL-1β/18 processing complex comparable to 
the AIM2 inflammasome. Remarkably, RIG-I would thereby act in a dual role in first 
triggering the production of pro-inflammatory cytokines in an IPS-1 dependent manner and 
secondly in controlling their processing in a similar way to the inflammasome (Poeck et al. 
2010).  
 
1.4.3. The AIM2 Inflammasome – a Cytosolic DNA sensor 
Sensors for cytoplasmic DNA have been investigated only recently. Thus, they still 
remain barely described and only a few have been identified. Best characterized is TLR9, 
which senses unmethylated CpG-rich DNA in endosomes (Chuang et al. 2002). Furthermore, 
the cytosolic PRR DAI has been shown to induce type I interferon production in response to 
foreign DNA (Takaoka et al. 2007). Also NLRP3 is implicated in capsase-1 activation 
specifically in response to adenoviral DNA only, likely involving another NLRP3 
inflammasome activating adaptor or secondary signal (Muruve et al. 2008). 
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With AIM2, a more general sensor of cytoplasmic DNA has now been described. AIM2 
initiates antiviral and inflammatory responses. It is capable of binding dsDNA with its 
C-terminal p200 (also HIN-200: Hematopoietic Interferon-inducible Nuclear proteins with a 
200-amino-acid repeat) domain, triggering association with ASC via homotypic Pyrin domain 
interactions. Upon subsequent recruitment of pro-caspase-1 by ASC’s CARD domain, 
complex formation is completed (Fig. 6) (Hornung et al. 2009).  
It is also believed that this subcomplex further assembles to a large multimeric complex, 
the actual inflammasome. This multimerization is not entirely clear, though. There are 
indications that it originates from AIM2, comparable to association of NLRs via the 
NBD/NACHT domain, or ASC oligomerization. Furthermore, the assembly of the 
macromolecular platform could be simply mediated by clustering upon multiple binding sites 
on the dsDNA ligand, via the HIN domain of AIM2 (Fernandes-Alnemri et al. 2009; Hornung 
et al. 2009). 
Upon inflammasome assembly pro-caspase 1 is auto-catalytically cleaved, resulting in 
active caspase-1 dimers. Thus processing of IL-1β and IL-18 from precursors and their 
subsequent release is achieved (Burckstummer et al. 2009; Hornung et al. 2009; Vilaysane et 
al. 2009).  
Furthermore, AIM2 was found to be interferon inducible and it has been shown to 
stimulate NF-κB dependent reporter gene activity when overexpressed in vivo (Hornung et al. 
2009).   
Figure 6 Schematic representations of the AIM2 inflammasome components and the 
way they interact upon binding of the HIN domain of AIM2 to dsDNA in the cytosol. 
 
1.4.4. AIM2 and the Interferon-Inducible p200 Protein Family 
A variety of p200-family proteins are found in human and mouse. They are encoded by 
IFN-inducible genes of the Ifi200 family. IFI-200 proteins were first identified as IFN-
inducible nuclear proteins and implicated in cell cycle regulation and differentiation 
(Landolfo et al. 1998). This was based on their ability to interact with and modulate the 
Introduction 
18 
 
activities of multiple transcriptional factors such as pRb (Retino Blastoma protein) and p53 
(Choubey et al. 1995; Dawson et al. 1996; Min et al. 1996; Johnstone et al. 2000; Ding et al. 
2004). 
In humans, four p200-family proteins have been identified so far, Interferon-Inducible 
protein 16 (IFI16), Myeloid Nuclear Differentiation Antigen (MNDA), IFN-inducible protein 
X (IFIX) and AIM2. Mice harbor some more members of this group, but AIM2 is the only 
real homolog between the two species (Choubey et al. 1995; Johnstone et al. 2000; Choubey 
et al. 2008; Zhang et al. 2009). Mouse AIM2 has been shown to function analogous to its 
human counterpart (Roberts et al. 2009). 
p200 family proteins are named after at least one shared partially conserved repeat of 200 
amino acid residues. This domain has been also termed HIN-200 domain (Hematopoietic 
Interferon-inducible Nuclear proteins with a 200-amino acid repeat), even though members 
have now been identified that are more ubiquitously expressed and appear cytoplasmic as well 
(Dawson et al. 1996; Roberts et al. 2009). HIN-200 consists of two consecutive 
oligonucleotide/oligosaccharide binding folds (OB-fold) that are required for DNA interaction 
(Albrecht et al. 2005). Most of the IFI-200 proteins, also AIM2, contain a Pyrin domain, a 
common motif associated with protein-protein interactions in the regulation of apoptotic and 
inflammatory signaling pathways. 
Furthermore, AIM2 and other p200 proteins harbor a conserved homo- or hetero-
dimerization motif, “MFHATVAT”, in their HIN domains. Another well conserved putative 
I/LxCxE pRb binding site is found in most p200 proteins but not AIM2 (Fig. 7) (Albrecht et 
al. 2005).  
Figure 7  Multiple sequence alignment of p200 proteins of human and mouse with the 
homo- or hetero-dimerization motif MFHATVAT and the I/LxCxE motif, implicated in pRb 
binding by some group members, underlined. Identical residues are depicted in white and 
shaded with red, homolog residues are shown in red. 
 
Most p200-family proteins harbor a classic nuclear localization signal (NLS) and are 
hence primarily detected in the nucleus. Exceptions are p202 in mouse and AIM2 in mouse 
and human that are preferentially cytosolic (Choubey et al. 2000; Ludlow et al. 2005). 
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Controversially, a nuclear localization of AIM2 has been demonstrated in one study 
(Cresswell et al. 2005). However, the NLS containing region found between the Pyrin and 
HIN domain in nuclear localized homologs is entirely missing in AIM2. Hence, a 
predominant cytosolic localization appears more reasonable. Also in a physiological context 
this seems more logical since AIM2 was shown to bind cytosolic dsDNA and thus 
inflammasome specks were also detected in the cytosol (Burckstummer et al. 2009; 
Fernandes-Alnemri et al. 2009; Hornung et al. 2009).  
The HIN-200 domain of AIM2 has been shown to bind DNA, with a preference for 
double strands, whereas the Pyrin domain associates with the adaptor molecule ASC to 
activate both NF-κB and caspase-1 (Hornung et al. 2009). Interestingly, mouse p202 has also 
been demonstrated to bind dsDNA in the cytosol, but it lacks the Pyrin domain, required for 
downstream interaction. Due to p202’s ability to heterodimerize with AIM2 it has been 
suggested to be a modulator of AIM2 activity in either inflammasome formation or NF-κB 
stimulation (Choubey et al. 2000; Roberts et al. 2009). For mouse p202 no human homolog 
has been found so far. It has however been suggested that splice variants of p200-family 
proteins might exist in humans that could act in a similar regulatory way (Ludlow et al. 2005; 
Lengyel et al. 2010).   
 
1.4.5. ASC – A Versatile Adaptor in Inflammation and Innate Immunity 
Apoptosis-associated Speck-like protein containing a CARD (ASC or PYCARD) was 
first identified by an antibody pulldown of insoluble components in retinoic acid exposed 
cells. The otherwise soluble, cytosolic 22-kDa protein exhibited intriguing behavior by 
forming aggregates and appeared as a speck in apoptotic cells treated with retinoic acid and 
other anti-tumor drugs (Masumoto et al. 1999). ASC harbors an N-terminal Pyrin domain 
(residues 1-92 for hsASC), a homotypic protein–protein interaction domain belonging to the 
six-helix bundle death domain (DD)-fold superfamily that includes DDs, death effector 
domains (DEDs), CARDs (Bertin et al. 2000; Fairbrother et al. 2001; Martinon et al. 2001; 
Pawlowski et al. 2001). Connected by a flexible linker PYD is followed by a C-terminal 
CARD (residues 116-195 for hsASC) that belongs to the same fold family (de Alba 2009). 
Both domains show an analogous architecture, although they have varying surface charge 
potentials and are in a back-to-back orientation. This acts to prevent steric interference of each 
domain with the binding site of the other (Fig. 8).  
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Figure 8 (A) NMR structure of full length ASC (PYCARD) with the N-terminal PYD 
shown in green and C-terminal CARD in purple. The electrostatic surface potential ranges 
from 5 kT (blue) to -5 kT (red). (B) Superposition of the six α-helix bundles of PYD and 
CARD of ASC. 
 
Both domains, CARD and even more so PYD, exhibit a certain polarity, therefore 
accounting for self association and filament formation effects that have been reported for ASC 
(Masumoto et al. 2001; Moriya et al. 2005; Cheng et al. 2010). ASC has been shown to form 
dimers that subsequently oligomerize. Consistently, interaction between the PYD and CARD 
domains of ASC can be either hetero- or homophilic (Masumoto et al. 2001). Furthermore 
oligomerization seems pH dependent (Gattin et al. 2008; Cheng et al. 2010) and cooperative, 
with speck formation being an “all or none” event (Cheng et al. 2010).   
Aside from a major part of hitherto identified inflammasomes (Fig. 5), ASC has been 
implicated in interaction with the pro-apoptotic protein Bax (BCL2-associated X protein) and 
the regulation of a p53–Bax mitochondrial pathway of apoptosis (Ohtsuka et al. 2004). Also 
binding to Pyrin and caspase-1 to form a pyroptosome has been shown (Fernandes-Alnemri et 
al. 2007; Yu et al. 2007). ASC was further found to interact with the viral RNA receptor
RIG-I (Poeck et al. 2010). Interaction is generally facilitated by a PYD-PYD contact; 
however evidence has been provided that ASC can be also involved in IPAF inflammasome 
formation despite a lack of an adaptor PYD in IPAF (Geddes et al. 2001). The latter is likely 
bound via the CARD that is otherwise required for caspase recruitment. In addition ASC has 
been shown to induce adaptive immune responses independently of caspase-1 inflammasomes 
and to be crucial for antigen-induced T-cell priming in dendritic cells (Ippagunta et al. 2010). 
Due to its versatility ASC is an excellent target for inflammasome regulation and 
modulation. Hence families of small proteins that are composed of either a CARD or a PYD 
only, emerged as important inflammasome regulators. These CARD-only proteins (COPs) 
and PYD-only proteins (POPs) function as endogenous dominant-negative proteins that 
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modulate activity of inflammasomes in response to pathogen infection and tissue destruction. 
The inhibitory effect is thereby either achieved by their binding to ASC directly or its 
interaction partners, in any case formation of functional inflammasomes by oligomerization of 
PYD and CARD containing components is disturbed (Stehlik et al. 2007).  
 
1.5. Objectives 
At the start of this PhD project, the field of cytosolic RLR signaling in innate immunity 
was only emerging. Especially little was known about the CARD-less RLR LGP2. A main 
goal was therefore the structural and functional dissection and characterization of this protein. 
This was for the purpose of gaining explanations for LGP2’s regulatory behavior towards 
RIG-I signaling and its specific RNA interaction modes. 
In this context, the general nature of RNA pattern recognition in RLRs was investigated. 
This was deemed to be of importance since sensitivity and specificity in ligand binding is 
crucial for proper RLR signaling and PRRs in general. Furthermore, the key towards 
understanding how RLRs discriminate between pathogenic, commensal, or intrinsic patterns 
lies in the molecular structure of the receptors. 
During the course of this thesis, AIM2, a new DNA specific PRR had been discovered by 
different groups. AIM2, as a cytosolic receptor of pathogenic DNA, was considered to make 
for a good comparison with LGP2 and RLRs and their role as receptors of viral RNA. 
Furthermore AIM2 had been reported to assemble into an unusual inflammasome upon DNA 
interaction and little functional or structural details were known. The direct (secondary) 
stimuli activating other inflammasomes are unclear. Therefore, the discovered AIM2 
inflammasome formation triggered by direct interaction with dsDNA can be considered as 
special. This makes it an ideal target for the first structural and functional analysis and in vitro 
reconstitution of a complete ligand bound inflammasomal complex. Moreover, certain 
intersections between the AIM2 inflammasome and RLR pathways became obvious. 
For these reasons, gaining insight into the DNA induced AIM2-ASC inflammasome 
subcomplex assembly became another goal of this PhD project. 
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2. Material and Methods 
2.1. Materials 
2.1.1. Chemicals 
All common chemicals were obtained from Roth (Karlsruhe, Germany) and Sigma 
(Deisenhofen, Germany), unless otherwise stated. Enzymes and nucleotides for molecular 
biology were supplied by MBI Fermentas (St. Leon-Rot, Germany) or New England Biolabs 
(Ipswich, MA, USA). 
Chromatographic systems, media and columns were purchased from GE Healthcare 
(München, Germany). DNA oligonucleotides for cloning were ordered from Eurofins MWG 
(München, Germany). RNA and DNA for crystallization and assays were acquired from 
Biomers (Ulm, Germany) or Thermo Scientific (Ulm, Germany). Synthetic 5’PPP RNA was 
obtained from Eurogentec (Köln, Germany). cDNAs were received from RZPD (Heidelberg, 
Germany) or ImaGenes (Berlin, Germany). 
Synthetic genes were obtained from Eurofins MWG (München, Germany) or Mr.Gene 
(Regensburg, Germany). Crystallographic tools and crystallization screens were purchased 
from Hampton Research (Aliso Viejo, CA, USA), Jena Bioscience (Jena, Germany), Corning 
(Amsterdam, Netherlands) and Qiagen (Hilden, Germany). 
 
2.1.2. Media and Supplements 
Luria Broth (LB) liquid media as well as LB Agar plates were prepared according to 
standard protocols (Sambrook et al. 1989). The media was supplemented with the respective 
antibiotics using stock solutions in 1:1000 dilutions (Table 2). Selenomethionine-containing 
protein was expressed in methionine auxotrophic E. coli strain B834 (Rosetta (DE3)) using 
LeMaster’s medium supplemented with selenomethionine (Hendrickson et al. 1990).  
 
Table 2 Antibiotic stock solutions 
Antibiotic Concentration (1000x) Solvent 
Ampicillin (Na-Salt) 100 mg/ml water 
Kanamycin 50 mg/ml water  
Chloramphenicol 34 mg/ml ethanol 
Tetraycline 12.5 mg/ml ethanol 
Gentamycin 10 mg/ml water 
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Insect cell media powder (Express Five) was purchased from Invitrogen (Karlsruhe, 
Germany) and solubilized according to the manufacturer’s protocol. Before use, the media 
was filter sterilized and supplemented with gentamycin (10 μg/ml) and glutamine (final 
concentration 18 mM). 
 
2.1.3. Bacterial Strains 
Table 3 Bacterial strains 
E.coli strain Genotype Source 
XL1 Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F´proAB 
lacIqZΔM15 Tn10 (TetR)] 
Stratagene, Heidelberg 
 
Rosetta (DE3) F– ompT hsdSB (rB– mB-) gal dcm (DE3) pRARE2 (CamR) 
Novagen, Madison USA 
 
B834 / DE3 F– ompT hsdSB (rB– mB-) gal dcm met (DE3) pRARE2 (CamR) 
Novagen, Madison USA 
 
DH10MultiBac not specified Imre Berger (Berger et al. 2004) 
 
 
2.1.4. Plasmids 
Table 4 Utilized plasmids 
Plasmid Expression System Source 
pET21a(+) E. coli Novagen, Madison USA  
pET28a(+) E. coli Novagen, Madison USA  
pFBDM Insect cells Imre Berger  (Berger et al. 2004)  
pGEX6P2 E. coli GE Healthcare, München, Germany  
pET28M-SUMO3-GFP E. coli EMBL, Heidelberg, Germany 
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2.1.5. Cloning and Mutagenesis Primer 
Table 5 Primer sequences used for cloning of constructs or site directed mutagenesis  
primer sequence (5‘  3‘) restriction site 
LGP2 537 fwd AAAAACAT|ATGGCAGCCCAGCGGGAGAACCA NdeI 
LGP2 543 fwd AAAAACAT|ATGCAGCGGCAGCAGTTCCCAGTG NdeI 
LGP2 671 STOP rev AAAAAGC|GGCCGCTCAGTTCTCGGCACAATG NotI 
LGP2 rev AAAAAGC|GGCCGCGTCCAGGGAGAGGTCCGAC NotI 
LGP2 STOP rev AAAAAGC|GGCCGCTCAGTCCAGGGAGAGGTCCGAC NotI 
LGP2 fwd AAAAACAT|ATGGAGCTTCGGTCCTACCAATG NdeI 
LGP2 549 fwd AAAAACAT|ATGGTGGAGCACGTGCAGCTACTCTG NdeI 
LGP2 C615A ATCAGCTGCAGGAACGCTGGGGAGGTCTGGGG - 
LGP2 H576Y GGTGGAGGGCACCTACCATGTCAATGTG - 
LGP2 K634E GCCAGTGCTCGAAGTCCGCAGCATGCTGC - 
LGP2 W604A GTCTTCAAGGACGCGAAGCCTGGGGGTGTC - 
LGP2 K605E CAAGGACTGGGAGCCTGGGGGTGTC - 
LGP2 P606K GTCTTCAAGGACTGGAAGAAAGGGGGTGTCATCAG - 
LGP2 L621A GGGGAGGTCTGGGGTGCGCAGATGATCTAC - 
LGP2 K626E GCAGATGATCTACGAGTCAGTGAAGCTGCC - 
LGP2 N583D GTCAATGTGAACCCCGACTTCTCGAACTAC - 
RIG-I 802 fwd AAAAACAT|ATGGATAAGGAAAATAA NdeI 
RIG-I STOP rev AAAAAGC|GGCCGCTCATTTGGACATTTCTGCTG NotI 
hAIM2 fwd AAAAAACAT|ATGGAGAGTAAATACAAGGAGATACTCTTGC NdeI 
hAIM2 STOP rev AAAAAAGC|GGCCGCCTATGTTTTTTTTTTGGCCTTAATAACC NotI 
hAIM2 rev AAAAAAGC|GGCCGCTGTTTTTTTTTTGGCCTTAATAACC NotI 
hAIM2 140 fwd AAAAAACAT|ATGGCCCAGCAGGAATCTATCAGAGAA NdeI 
mAIM2 fwd AAAAAACAT|ATGGAGAGTGAGTACCGGGAAATG NdeI 
mAIM2 146 fwd AAAAAACAT|ATGGCAGAACAGGAAGCCATCAGAGA NdeI 
mAIM2 STOP rev AAAAAAGC|GGCCGCTCACTCCACACTTTTCATGTCAGTTTT NotI 
mAIM2 rev AAAAAAGC|GGCCGCCTCCACACTTTTCATGTCAGTTTT NotI 
mAIM2 94  fwd AAAAAACAT|ATGACCAATACAAAGAAGAG NdeI 
mAIM2 137 fwd AAAAAACAT|ATGGCTAAGCCTCAGAAGAAACAG NdeI 
mASC 93 syn STOP rev  AAAAAAGC|GGCCGCTTAGCCTGATTCTTCTTTGG NotI 
mASC syn STOP  rev AAAAAAGC|GGCCGCTTAGGATTGCTCCAG NotI 
mASC syn fwd AAAAAAG|GATCCATGGGTCGTGCTCGTG BamHI 
mASC syn fwd AAAAAAA|CCGGTATGGGTCGTGCTCGTG AgeI 
mASC syn fwd AAAAAACAT|ATGGGTCGTGCTCGTG NdeI 
hASC syn fwd AAAAAAG|GATCCATGGGACGTGCTCGGG BamHI 
hASC syn fwd AAAAAAA|CCGGTATGGGACGTGCTCGGG AgeI 
hASC syn fwd AAAAAACAT|ATGGGACGTGCTCGGG NdeI 
hASC fwd AAAAAACAT|ATGGGGCGCGCGCGCGACGCC NdeI 
hASC STOP rev AAAAAAGC|GGCCGCTCAGCTCCGCTCCAGGTCCTCC NotI 
hASC syn 92 STOP rev AAAAAAGC|GGCCGCTCAGCCCTGGTGCGTGGCCGCCTC NotI 
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2.1.6. RNA and DNA Oligonucleotides 
Table 6 Applied RNA oligonucleotides (syn: synthetic; ivt: in vitro transcribed; s: 
sense; as: antisense; hp: hairpin; nt: nucleotides; AF: AlexaFluor; RVL: Rabies Virus Leader; 
FAM: Carboxyfluorescein; DZT: DNAzyme target; RZ: ribozyme) 
 
 
RNA company modification name sequence MW [kDa] 
syn Metabion 5’OH 19 s GCAUGCGACCUCUGUUUGA 6.2 
syn Metabion 5’OH 19 as UCAAACAGAGGUCGCAUGC 6.3 
syn Eurogentec 5’PPP 19 s GCAUGCGACCUCUGUUUGA 6.5 
ivt Ambion (Kit) 5’PPP 18 s/as hp 
GGCAUGCGACCUCUGU
UUGAUCAAACAGAGGU
CGCAUGCC 
13.3 
ivt Ambion (Kit) U-AF488 18 s/as hp 
GGCAUGCGACCUCUGU
UUGAUCAAACAGAGGU
CGCAUGCC 
>13.3 
syn IBA 5’AF488 25 s GCUUGUCGGGAGCGCCACCCUCUGC 8.8 
syn biomers.net 5’OH 25 as GCAGAGGGUGGCGCUCCCGACAAGC 8.3 
ivt Ambion (Kit) or recombinant T7 Pol 5’PPP RVL 58nt 
ACGCTTAACAACCAGA
TCAAAGAAAAAACAGA
CATTGTCAATTGCAAA
GCAAAAATGT 
18.0 
syn Biomers.net 5’ 6-FAM 27 s ACGCUUAACAACCAGAUCAAAGAAAAA 9.3 
syn Biomers.net - 27 as UUUUUCUUUGAUCUGGUUGUUAAGCGU 8.5 
ivt Ambion (Kit) 5’PPP DZT GGGGAAUU|GUGAGCGG  
ivt Ambion (Kit) or recombinant T7 Pol - RZ 
NNN|GCUAGCCAUGGU
CCCAGCCUCCUCGCUG
GCGGCUAGUGGGCAAC
AUGCUUCGGCAUGGCG
AAUGGGACUUUAAAC 
24.2 
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Table 7  Applied DNA oligonucleotides (syn: synthetic; s: sense; as: antisense; hp: 
hairpin; FAM: Carboxyfluorescein; DZ: DNAzyme) 
DNA company modification name sequence MW [kDa] 
syn Biomers.net - 11 hp GGGCTAGGCGGGCGACCGCCTAGCCC 8.0 
syn Biomers.net - 18 hp 
CACTATAGGGCTAGGCGG
GCGACCGCCTAGCCCTAT
AGTG 
12.3 
syn Biomers.net - 25 hp 
TACGACTCACTATAGGGC
TAGGCGGGCGACCGCCTA
GCCCTATAGTGAGTCGTA 
16.6 
syn Thermo Scientific 3’ 6-FAM 11 hp GGGCTAGGCGGGCGACCGCCTAGCCC 8.6 
syn Thermo Scientific 3’ 6-FAM 18 hp 
CACTATAGGGCTAGGCGG
GCGACCGCCTAGCCCTAT
AGTG 
12.9 
syn Thermo Scientific 3’ 6-FAM 25 hp 
TACGACTCACTATAGGGC
TAGGCGGGCGACCGCCTA
GCCCTATAGTGAGTCGTA 
17.2 
syn Biomers.net - 8 s GGGCTGGG 2.5 
syn Biomers.net - 8 as CCCAGCCC 2.3 
syn Thermo Scientific 5-Br-dC 11 hp GGGCTAGGCGGGCGACCGCCTAGCCC 8.8 
syn Biomers.net 5-Br-dU 18 hp 
CACTATAGGGCTAGGCGG
GCGACCGCCTAGCCCTAT
AGTG 
12.8 
syn Biomers.net - 35 s GTGTTGATGAAGGGGGGCTATAAAAGGGGGTGGGG 11.1 
syn Biomers.net 5’ ATTO488 35 as CCCCACCCCCTTTTATAGCCCCCCTTCATCAACAC 11.1 
syn MWG - DZ I CTCACA|GGCTAGCTACAACGA|TTCCCC 8.2 
syn MWG - DZ II TCCGCTCA|GGCTAGCTACAACGA|AATTCCCC 9.5 
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2.2. Methods 
2.2.1. Molecular Biological Methods 
Molecular biology manipulations were conducted according to standard protocols 
(Sambrook et al. 1989) or as described subsequently. 
 
2.2.1.1. Molecular Cloning 
All PCR primers (Table 5) were designed considering melting temperature, overlap with 
the template DNA, appropriate restriction sites and harbored a 5’ overhang of 6 adenosines 
for improved restriction efficiency. Standard PCR reaction mixes contained 10 µl 2x 
Phusion® Flash High-Fidelity PCR Master Mix (Finnzymes, Espoo, Finland), 8.5 µl water, 
0.5 µl template DNA (~30-100 ng/µl in water) and 0.5 µl of each reverse and forward primer 
(50 pmol/µl in water). PCR cycles were applied as follows: 
 
1) 98 °C    30 s 
2) 98 °C      1 s 
3) 57 °C      5 s 
4) 72 °C    15 s / 1kb 
   repeat 2) – 4) 30 to 35 times 
      72 °C  300 s 
 
Subsequently, the respective restriction enzymes and buffers were added straight to the 
PCR reactions. Amounts added varied depending on the duration of the digest (~ 3 hours or 
overnight) or the supplier’s instructions for double digests. Typically 2.5 µl 10 x buffers and 
1.25 µl of each enzyme were added to the 20 µl PCR mix. Destination vectors were treated 
accordingly and in addition dephosphorylated by addition of Fast Alkaline Phosphatase for an 
hour after the digest. Enzymes were inactivated and released from the DNA strands by 
incubating at 65 °C for 10 min. 
PCR products were analyzed on 1 % (w/v) agarose gels (TAE buffer system: 50x TAE – 
242g TRIS base, 100 ml 0.5M EDTA pH 8.0, 57.1 ml glacial acetic acid, ad 1 l H2O) and 
extracted from excised gel slices with a Metabion (Martinsried, Germany) gel extraction kit. 
DNA was then eluted in a volume of 30 µl water.  
For ligations the digested PCR fragment and vector were added in a 4:1 ration (usually 8 
µl of gel extracted insert and 2 µl of vector) with 2 µl 10x ligation buffer and 1 µl T4 DNA 
ligase in a total volume of 20 µl. Ligation reactions were carried out at 22 °C for 1 hour or 
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over night at 19 °C and terminated by a 10 min incubation at 65 °C. 10 µl of the ligation mix 
were then transformed into E. coli XL1 blue cells. Utilized vectors are listed in Table 4. 
 
2.2.1.2. Site Directed Mutagenesis 
Site directed mutations were introduced, according to the Quikchange protocol from 
Stratagene (Agilent Technologies, Santa Clara, CA, USA), using mutagenic primers and the 
Phusion® Flash High-Fidelity PCR Master Mix (Finnzymes, Espoo, Finland) analog to the 
standard PCR protocol but with 0.5 µl of 20 pmol/µl mutagenic primers. Subsequent to the 
amplification of the whole plasmid in 20 PCR cycles, methylated template plasmid containing 
the wildtype sequence was digested by addition of DpnI. 10µl of the PCR mix were then 
transformed into E. coli XL1 blue cells. Used mutagenic primers are listed in Table 5. 
 
2.2.1.3. Transformation 
Transformations were performed with chemically competent cells. 10 µl from ligation 
mixtures or 0.5 – 2 µl of purified Plasmid (50 – 300 ng/µl), respectively were added to 70 µl 
of competent cells and incubated on ice for 15 min. Cells were then heat shocked (45 s at 
42 °C) followed by a 2 min incubation on ice, addition of 900 µl LB medium and subsequent 
incubation on a thermo shaker at 37 °C for 1 hour to establish antibiotic resistance. Bacterial 
hosts that were used are listed in Table 3.     
 
2.2.1.4. Plasmid Preparation 
Plasmids were obtained from 4 ml of overnight culture of E. coli XL1 blue cells after 
lysis and extraction from cell pellets using a Metabion Miniprep kit in a volume of 50 µl 
water with typical concentrations between 50 and 300 ng/µl.  
 
2.2.1.5. Bacmid Preparation 
pFBDM vectors were transformed into E. coli DH10 MultiBac cells for integration into 
bacmids. After heat shock, cells were taken up into 900 µl 2xYT medium and incubated for at 
least 5 hours shaking at 37°C to establish antibiotic resistance. Cells were then plated on LB 
agar containing gentamycin, kanamycin, tetracyclin, IPTG and X-Gal for blue white 
screening, and selection of a colony with an integrated plasmid (white). Bacmids were 
prepared from a 200 ml overnight culture using a Qiagen Midiprep kit. Ethanol precipitated 
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bacmid DNA was usually taken up in 100µl water typically yielding bacmid concentrations 
around 1 µg/µl. Purified bacmid DNA was stored at 4°C.  
 
2.2.2. Protein Biochemical Methods 
2.2.2.1. Protein Expression in Insect Cells 
To generate a first generation of baculovirus, 5 µg of bacmid DNA were pre-incubated 
with 2 µl FuGene (Roche, Penzberg, Germany) and 200 µl of High Five medium (Invitrogen, 
Karlsruhe, Germany) for 45 min at room temperature. Meanwhile 2 ml of High Five insect 
cells (Invitrogen, Karlsruhe, Germany), freshly diluted in High Five medium to 0.25 Mio/ml 
cell density, were transferred to a 6 well tissue culture plate and incubated at 27.5 °C. After 
transfection with the premix, infected cells and one uninfected control per plate were 
incubated for 48-60 h at 27.5 °C as adhesive culture. The supernatant containing virus 
generation 0 (V0) could then be collected and was used for amplification of the viral titer by 
transferring it to 50 ml freshly diluted 0.5x106 ml High Five insect cells in 500 ml flasks. 
Cells were incubated for 3-4 days at 27.5 °C and 85 rpm in shaking culture. Cell growth was 
monitored during this and cells were diluted if necessary to prevent growth over 3x106 cells 
per ml. Normally, cell growth would be arrested after 1-2 days and the culture is further 
incubated for 1-2 more days for best expression results. V1 could be obtained in the 
supernatant after spinning down the cells and was used for further up-scaling of the 
expression. Up to 3 virus generations were produced in increasing culture volumes for final 
expression, which was performed in 1 l cultures in 5 l flasks with according concentrations. 
Cells were harvested by centrifugation, flash frozen in liquid nitrogen and stored at -20°C. 
The supernatant containing high viral titers was utilized for further expression and stored at
4 °C. 
 
2.2.2.2. Protein Expression in E.coli 
Expressed constructs with vectors and expression host are listed in Table 8. Pre-cultures 
of 30 ml per 3 l expression were inoculated with 1 colony of freshly transformed and plated 
cells and grown over night at 37 °C in a shaking incubator. 3 l LB were then inoculated with 
pre cultures 1:100 and grown in shaking culture to an OD600 of 0.8 at 37°C. Protein 
production was started by addition of 0.13 – 0.5 mM IPTG and the cells were shaken over 
night at 18°C. After harvesting, collected cell pellets were flash frozen in liquid nitrogen and 
stored at -20 °C.  
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2.2.2.3. Protein Purification 
Fresh or thawed cell pellets were resuspended in lysis buffer (~30 ml/3 l bacterial or 
1 l insect cell pellet) and disrupted by sonication (15 min, duty cycle 7, output control 50% 
for E. coli or 5 min and additional stirring of the lysate on ice for insect cells). Whole cell 
lysate was spun for 30 minutes at 16000 rpm in a Sorvall (Newport Pagnell, UK) centrifuge, 
SS-34 rotor, prior to draining the supernatant off the pellet of cell debris and keeping it for 
downstream purification. Supernatants sometimes had to be either filtered or centrifuged 
again to remove remaining insoluble particles.  
Depending on the protein properties and presence of a tag, purification steps included 
affinity chromatography, ion exchange chromatography (IEC) and size exclusion 
chromatography (SEC or gelfiltration), typically as last step. All purification steps were 
followed by analyzing the respective protein containing fractions by SDS PAGE 
(discontinuous Laemmli-system in TGS buffer: 10x – 720.5g Glycine, 0.5 l 10% w/v SDS, 
151.5 g TRIS base, ad 5 l H2O) (Laemmli 1970). Given a high enough purity fractions from 
size exclusion chromatography were then pooled and the proteins concentrated via ultra 
filtration in centrifugal filter devices (Millipore, MA, USA) with an appropriate molecular 
weight cutoff. Depending on their stability and experimental use proteins were typically 
concentrated to between 1 and 20 mg/ml. Respective purification steps are described 
subsequently in detail and are listed together with applied buffers for all constructs in Table 8. 
 
2.2.2.3.1. Glutathione-S-Transferase Affinity Chromatography 
Glutathione-S-transferase (GST) tagged constructs were in a first purification step 
applied to a glutathione coupled sepharose resin. Elution of the protein was achieved by 
competition with buffer containing free glutathione. The GST-tag was cleaved subsequently 
with PreScission protease (GE Healthcare, München, Germany) followed by either 
gelfiltration or another GST-affinity chromatography step to retain the free tag. 
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Table 8 Constructs, Expression host and Purification Steps 
Construct Expression host Purification step Buffer 
pET28 
6xHis - 
LGP2 RD 
E. coli 
Rosetta DE3 
Nickel-NTA 
30mM TRIS-HCl pH 7.5; 10/50/100/250mM 
Imidazole; 0.1M NaCl; 5% Glycerol; 1mM β-
Mercaptoethanol 
SP-Sepharose 30mM TRIS-HCl pH 7.5; 0.1/1M NaCl, 5% Glycerol; 2mM DTT 
Superdex S75 30mM TRIS-HCl pH 7.5; 0.15M NaCl, 5% Glycerol; 2mM DTT 
pET21a 
LGP2 RD 
(537/543/ 
549-678) 
E. coli 
Rosetta DE3 
SP-Sepharose 30mM TRIS-HCl pH 7.5; 0.1/1M NaCl, 5% Glycerol; 2mM DTT 
Superdex S75 30mM TRIS-HCl pH 7.5; 0.15M NaCl, 5% Glycerol; 2mM DTT 
pFBDM 
6xHis - 
LGP2 full 
High Five 
Insect Cells 
Nickel-NTA 
30mM TRIS-HCl pH 7.5; 10/50/100/250mM 
Imidazole; 0.1M NaCl; 5% Glycerol; 1mM β-
Mercaptoethanol 
Q-Sepharose 30mM TRIS-HCl pH 7.5; 0.1/1M NaCl, 5% Glycerol; 2mM DTT 
Superdex S200 30mM TRIS-HCl pH 7.5; 0.15M NaCl, 5% Glycerol; 2mM DTT 
pET21a 
RIG-I RD 
(802-925) 
E. coli  
Rosetta DE3 
SP-Sepharose 30mM TRIS-HCl pH 7.5; 0.1/1M NaCl, 5% Glycerol; 2mM DTT 
Superdex S75 30mM TRIS-HCl pH 7.5; 0.15M NaCl, 5% Glycerol; 2mM DTT 
pET28 
(N-His) 
/pET21a 
(C-His) 
6xHis – 
AIM2 
(various) 
E. coli  
Rosetta DE3 
Nickel-NTA 
30mM TRIS-HCl pH 7.5; 10/50/100/250mM 
Imidazole; 0.1M NaCl; 5% Glycerol; 1mM β-
Mercaptoethanol 
SP-Sepharose 30mM TRIS-HCl pH 7.5; 0.1/1M NaCl, 5% Glycerol; 2mM DTT 
Superdex S200 30mM TRIS-HCl pH 7.5; 0.15M NaCl, 5% Glycerol; 2mM DTT 
pET21a 
AIM2 full 
length 
E. coli 
Rosetta DE3 
Heparin 30mM TRIS-HCl pH 7.5; 0.4/1M NaCl, 5% Glycerol; 2mM DTT 
Superdex S75 30mM TRIS-HCl pH 7.5; 0.15M NaCl, 5% Glycerol; 2mM DTT 
SP-Sepharose 30mM TRIS-HCl pH 7.5; 0.1/1M NaCl, 5% Glycerol; 2mM DTT 
pET21a 
AIM2 HIN 
(various) 
E. coli 
Rosetta DE3 
Heparin 30mM TRIS-HCl pH 7.5; 0.4M NaCl, 5% Glycerol; 2mM DTT 
SP-Sepharose 30mM TRIS-HCl pH 7.5; 0.1/1M NaCl, 5% Glycerol; 2mM DTT 
Superdex S75 30mM TRIS-HCl pH 7.5; 0.15M NaCl, 5% Glycerol; 2mM DTT 
pGEX6P2 
GST-ASC 
(various) 
E. coli 
Rosetta DE3 
GSH-Sepharose 50mM HEPES or MES pH 6.5; 0.15M NaCl, 5% Glycerol; 2mM DTT; 0/20mM Glutathione 
Superdex S75 50mM HEPES or MES pH 6.5; 0.15M NaCl, 5% Glycerol; 2mM DTT 
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2.2.2.3.2. Nickel Affinity Chromatography 
Constructs containing an N-terminal 6xHis-Tag were initially purified by immobilized 
metal affinity chromatography. 2 ml (~4 ml slurry in 20% ethanol) of nickel charged NTA 
resin (Qiagen) were filled into an empty Econo-Pac column (Biorad, CA, USA) suited for 
gravity flow chromatography, rinsed with water and then equilibrated with 5 column volumes 
(cv) of lysis buffer containing 10 mM imidazole to reduce unspecific binding. After loading 
the protein sample to the resin, unspecifically bound protein was removed by a wash step with 
5 cv of equilibration buffer. To ensure high protein purity in the elution fractions two 
additional washing steps were applied with 2x 2 cv each of buffers containing 50 mM and
100 mM imidazole, respectively. Finally 3-5 x 2 cv of elution buffer containing 250 mM 
imidazole were applied to the column. Fractions were collected accordingly for all wash and 
elution steps and further analyzed by SDS PAGE. Depending on the protein purity pooled 
fractions were either dialyzed in low salt buffer for subsequent ion exchange chromatography 
or concentrated for size exclusion chromatography. 
 
2.2.2.3.3. Heparin Affinity Chromatography 
DNA binding constructs were initially purified with a 5 ml HiTrap Heparin HP column 
allowing for a higher salt concentration in the lysis / binding buffer than for ion exchange 
chromatography. Binding buffers usually contained 400 mM NaCl and elution (1.5 ml 
fractions) of bound proteins was achieved by applying a 20 cv linear gradient from 0 to 100 % 
1 M NaCl high salt buffer. Buffers used had physiological pH or slightly lower. Due to 
insufficient purity this was usually followed by dialysis of the pooled fractions to low salt 
buffer and cation exchange chromatography.   
 
2.2.2.3.4. Dialysis 
In order to change the buffer of a large volume of protein it was subjected to overnight 
dialysis in a buffer rinsed nitrocelluose tubing (Roth, Karlsruhe, Germany) with stirring, in 2 l 
of dialysis buffer (usually low salt binding buffer for IEC) at 4°C. 
 
2.2.2.3.5. An- and Cation Exchange Chromatography  
Considering their theoretical pI, constructs were either subjected to an- or cation 
exchange chromatography as a first purification step or following affinity chromatography. 
Material and Methods 
33 
 
For proteins with pI values above 7.5 a cation exchange 5 ml HiTrap SP Sepharose FF 
column was used in a buffer system with a pH about 2 units below the pI, if applicable. 
Proteins with a pI below 7.5 were purified applying an anion exchange 5 ml HiTrap Q 
Sepharose FF column and a buffer about 2 pH units above the pI. Columns were equilibrated 
with 5 cv low salt binding buffer prior to loading the proteins with a membrane pump (GE 
Healthcare), followed by a 5 cv wash step with binding buffer. The binding buffer contained 
100 mM NaCl and elution of the proteins was achieved by applying a linear gradient of 20 cv 
from 0 to 100 % high salt buffer containing 1 M NaCl on an ÄKTA system. Fractions of 
1.5 ml were collected. Pooled fractions were then concentrated for size exclusion 
chromatography.  
 
2.2.2.3.6. Size Exclusion Chromatography (SEC or Gelfiltration) 
For preparative SEC either a Superdex S200 26/60 (mainly proteins > 70 kDa) or 
Superdex S75 26/60 (mainly smaller proteins < 70kDa) have been used with an ÄKTA 
Purifier. Protein samples were concentrated to at least 2 ml and spun in a tabletop centrifuge 
(Eppendorf, Hamburg, Germany) for 10 min at 13000 rpm and 4°C before injection to the 
column. Fractions of 1 ml were collected during elution. 
Analytical SEC was carried out on an ÄKTA Ettan system using either Superose 6 or 12 
3.2/30 and sample loading volumes of 10 µl.   
 
2.2.3. Crystallographic Methods 
2.2.3.1. Crystallization 
LGP2 RD was screened for crystallization using common screens from Qiagen and Jena 
Bioscience. Initial screens were setup in 96 well sitting drop plates with a Hydra II-Plus-One 
robot (Matrix Technologies, Thermo Fisher Scientific, USA) and drop sizes varied between 
0.1 and 0.5 µl. Crystallization screening was tested with and without addition of TCEP. LGP2 
RD was crystallized using hanging drop vapor diffusion by mixing 2 µl of protein solution at 
13 mg/ml protein concentration with 2 µl of the reservoir solution (500 µl: 1.5 M (NH4)2SO4, 
100 mM TRIS-HCl pH 8.5, 0.5 mM TCEP). Crystals grew after several weeks at 21°C.  
RIG-I RD/RNA and AIM2/DNA complexes were screened using a Phoenix robot (Art 
Robbin’s, Sunny Vale, CA, USA) and common screens and were refined by either hanging or 
sitting drop methods. 
Material and Methods 
34 
 
2.2.3.2. Crystallographic Data Collection of LGP2 RD  
Prior to flash freezing in liquid nitrogen, the LGP2 RD crystals were soaked with 2 mM 
mercury acetate for 10 minutes and then transferred for 5-10 seconds into the reservoir 
solution additionally containing 2.5 M (NH4)2SO4. The final diffraction data was collected at 
the theoretical absorption edge of mercury with a wavelength of 1.009 Å at ESRF beamline 
ID 14-4 (European synchrotron radiation facility, Grenoble, France).  
 
2.2.3.3. Structure Determination of LGP2 RD 
2.2.3.3.1. Theoretical Background 
Diffraction experiments only yield the intensities of scattered waves arising from the 
atomic distribution of the molecule within a lattice, while the phases are lost. Hence, in order 
to produce an interpretable image from experimental data, it is necessary to determine the 
associated phases. Basically, no formal relationship between amplitudes and phases exist, so 
they can only be accessed via the molecular structure or electron density itself.  
Various methods have been established to gain estimates of phases that can then be used 
to derive more accurate phase values. Such methods include direct methods that require 
extremely high resolution and completeness, molecular replacement that employs homolog 
structures with significant sequence identity, and various methods involving heavy metal 
soaking or derivatization as a means of introducing anomalous scatterers.   
The electron density function is given as a Fourier transform of the structure factors that 
are represented by amplitudes Fhkl and phases ϕhkl: 
 
𝜌𝜌(𝑥𝑥, 𝑦𝑦, 𝑧𝑧) = 1V� |Fhkl | ∙ e−2πi∙(hx +ky +lz−ϕhkl ) 
ℎ𝑘𝑘𝑘𝑘
 
 
The Patterson function however, replaces the structure factors with the 
squared amplitudes only, whose values are proportional to the diffraction intensities, leaving 
phases aside: 
𝜌𝜌(𝑢𝑢, 𝑣𝑣,𝑤𝑤) = 1V� |Fhkl |2 ∙ e−2πi∙(hu +kv +lw ) 
ℎ𝑘𝑘𝑘𝑘
 
 
with      |Fhkl |2  ∝ 𝐼𝐼ℎ𝑘𝑘𝑘𝑘 
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Thus, the Patterson Function can be directly calculated from the experimental data 
obtained in the diffraction experiment and a Patterson map, which represents interatomic 
distances, can be derived.  
For molecular replacement the Patterson maps of a suited search model and the 
calculated experimental Patterson map are compared and a solution is found when best 
congruency is reached. In this approach six dimensions have to be considered, that can 
however be split up in the model search process. First a three dimensional rotational function 
is applied to determine the relative orientation of the unknown structure and secondly the 
position is derived by translation in three directions. Ideally the so calculated position of the 
molecule can be used to derive phases that should be accurate enough to allow for obtaining 
an electron density map (Taylor 2003).  
A newer and more accurate approach for MR uses maximum-likelihood (Read 2001). It 
assesses the agreement of the model derived theoretical data with the experimental one by 
using probabilities. The model to be tested includes, aside from the structure, orientation and 
position of that template in the unit cell of the target, also parameters describing the sizes of 
different sources of error. Thus, replacement with weak homology models and in cases of 
many molecules in the asymmetric unit becomes more efficient. 
Another means of solving the phase problem is the introduction of anomalous scatterers, 
i.e. heavy atoms into the protein crystals. This is either achieved by soaking the crystals in 
heavy metal solutions or by growing selenomethionine containing protein crystals. The 
simplest and least radiation damage causing phasing methods using anomalous scattering are 
single-wavelength anomalous dispersion (SAD) or single isomorphous replacement with 
anomalous scattering (SIRAS). Thereby, the exposure of the heavy atom derivative crystals to 
a certain wavelength x-ray beam that ideally lies at the absorption edge of the included heavy 
atoms, for example 1.009Å for mercury, causes anomalous dispersion. In addition to elastic 
scattering the incident x-ray wave is absorbed, causing a slight retardation and phase shift of 
the scattered wave. Even though, resulting phases still underlie a twofold ambiguity, 
sufficiently good phase estimates can be gained by including probabilities and use of density 
modification methods (Dodson 2003; Taylor 2003; Taylor 2010).  
 
2.2.3.3.2. Solution of the LGP2 RD Structure 
Diffraction data were processed with XDS (Kabsch 1993). Heavy atom sites were 
located using autoSHARP (Vonrhein et al. 2007) and an initial experimental electron density 
map could be derived. Due to high sequence similarity, the structure was then however 
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determined by molecular replacement with Phaser (McCoy et al. 2007a), using human RIG-I 
RD (PDB entry 2QFB,(Cui et al. 2008)) as a search model. The resulting 2Fo-Fc and Fo-Fc 
electron density maps allowed initial manual model building. The model was iteratively 
refined by cycles of bulk solvent correction, overall anisotropic B factor refinement, 
positional refinement and overall B factor refinement with CNS 1.2 (Brunger 2007) and 
Phenix (Adams et al. 2002). Initial non crystallographic symmetry restraints were gradually 
removed in the final cycles of the refinement, to allow some structural variations. Manual 
model building was performed with Coot (Emsley et al. 2004) and solvent atoms added with 
CNS 1.2.  
 
2.2.4. RNA and DNA Biochemistry 
Double strands were annealed in a thermo cycler by first heating to 95°C for 5 min, then 
stepwise lowering of the temperature to 4°C and stored at -20°C. 3’ ends were unmodified, if 
not stated differently. Fluorescent labels were either located at 5’ or 3’ ends or throughout the 
oligonucleotide when incorporated by in vitro transcription. RNA and DNA hairpins were 
annealed by heating at 95°C for 5 min and immediate incubation on ice to avoid annealing of 
two complementary strands rather one intrinsically. DNA oligonucleotides used for AIM2 
binding assays and co-crystallization are listed in Table 7. 
 
2.2.4.1. RNA Preparation 
In general RNA was handled according to standard procedures with  transcription and T7 
Polymerase purification protocols used as described in the “Handbook of RNA Biochemistry” 
(Hartmann et al. 2005).  
5’-triphosphate containing RNA for binding assays was either obtained by in vitro 
transcription using the Ambion (Austin, TX, USA) MEGAshortscriptTM Kit (or purchased 
from Eurogentech (Köln, Germany). RNAs from in vitro transcription mixes were purified 
using MicroSpinTM G-50 columns (GE Healthcare) or reversed phase chromatography (µRPC 
C2/C18 2.1/100 column; solvents: 8.6 mM TEA, 100 mM HFIP in either H2O for loading or 
methanol for elution) and checked for purity by denaturing urea PAGE (12-20 % (w/v) acryl-/ 
bisacrylamide, 6M urea, 1x TBE). RNAs were fluorescence labeled by either incorporating 
AlexaFluor 488-5-UTP during in vitro transcription or purchased from IBA with AlexaFluor 
488 as 5’ modification. Unmodified oligonucleotides were purchased from Metabion or 
biomers.net. Used RNAs are listed in Table 6. RNAs for co-crystallization with RIG-I RD 
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were also obtained by in vitro transcription using either T7 RNA polymerase purified in the 
lab or the Ambion MEGAshortscriptTM Kit. Dideoxy-UTP or AlexaFluor 488-5-UTP were 
thereby incorporated to achieve homogenic 3’-ends by polymerization break-off.  
 
2.2.4.2. Ribozymes and DNAzymes 
As another means of producing homogenic RNAs, ribozyme transcription and auto-
cleavage was conducted. Ribozyme templates used were derived from a human delta virus 
(HDV) ribozyme containing vector (Walker et al. 2003). The ribozyme template containing 
vector was first amplified, then linearized by XhoI digest and then purified by gelextraction. 
After a 37 °C over night in vitro transcription step the reaction mixture was subjected to a 
thermo cycle optimized for ribozyme cleavage (6x repeat: 1 min at 72 °C, 5 min at 65 °C,
10 min at 37°). Ribozyme cleavage products were analyzed in 6 M urea/ 12 % polyacrylamide 
(in 1x TBE) gels and detected by UV shadowing. 
DNAzymes were also tested under standard conditions to gain homogeneous 3’ ends and 
short RNAs (Schubert et al. 2003). Applied oligonucleotides are listed in Tables 6 and 7. 
 
2.2.5. Biochemical Assays 
2.2.5.1. Fluorescence Anisotropy Measurements 
Fluorescence anisotropy experiments were performed with a FluoroMax-3P fluorimeter 
(HORIBA Jobin Yvon, Unterhaching, Germany), equipped with Glan-Thompson prism 
polarizers and a temperature stabilized cuvette holder (connected to a Haake F3 thermostat). 
Typically, 1 ml of buffer (30 mM TRIS-HCl pH 7.5, 150 mM NaCl, 2 mM DTT, and 10 µM 
ZnCl2) and 37 nM RNA (5’ AlexaFluor 488 labeled/ 5’OH dsRNA, 25 bp) were pre-
equilibrated in a quartz cuvette at 12 °C. Protein samples were added in a stepwise manner. 
After mixing and 4 minutes of incubation to reach equilibrium, anisotropy data was collected 
using an excitation wavelength of 495 nm and monitoring the emission at 516 nm. The band 
pass was 5 nm for excitation and 5 nm for emission. A maximum number of ten trials were 
performed until minimal deviation of the signal was reached. For the competition assays 
800 µl of buffer, 40 nM of an in vitro transcribed hairpin RNA (AlexaFluor 488-5-UTP 
incorporated), and 470 nM protein were pre-equilibrated in a quartz cuvette at 12°C. 
Unlabeled RNA species were added in a stepwise manner and the drop in anisotropy was 
monitored after mixing and 4 minutes of re-equilibration.  
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Data were fitted applying a simplified single-site binding model by non-linear least 
square fitting using the Origin (Northhampton, MA, USA) data analysis software:  
 
𝛥𝛥𝛥𝛥 = 𝛥𝛥𝑚𝑚𝑚𝑚𝑥𝑥 ∗ 𝑥𝑥
𝐾𝐾𝑑𝑑 + 𝑥𝑥  
 
where ΔA is the measured anisotropy difference, x the applied protein concentration and Kd 
the deduced dissociation constant. 
 
2.2.5.2. Electrophoretic Mobility Shift Assays 
Electrophoretic mobility shift assays were carried out using 10% (w/v) polyacrylamide 
native gels in TRIS borate buffer (5x – 54 g/l TRIS, 27.5 g/l borate). Samples contained 5% 
glycerol, 60 nM 5’ AlexaFluor 488 labeled/5’-OH dsRNA (25 bp) and different 
concentrations of protein, diluted from 5 µM stock solutions (in 30 mM TRIS-HCl pH 7.5, 
150 mM NaCl, 2 mM DTT and 10 µM ZnCl2). Samples were incubated for 20 minutes at 4°C 
prior to electrophoretic analysis. Gels were analyzed with a TyphoonTM scanner (GE 
Healthcare).  
 
2.2.5.3. Pulldown Assays 
To determine physical interaction between C- or N-terminally Hexa-His-tagged 
h/mAIM2 and GST-tagged h/mASC or its PYD respectively, pulldowns were performed on 
GSH-Sepharose resin, immobilizing the ASC component. MES buffers at pH 6.5 containing 
150 mM NaCl and 2 mM β-mercaptoethanol were used and supplemented with imidazole, 
more salt (wash step of Ni-NTA immobilized AIM2) or GSH as required. Proposed binding 
partners were either expressed together (different but compatible vectors, N-terminal 6xHis 
AIM2) or separately (C-terminal 6xHis-tag for AIM2) in 100 ml cultures of E.coli Rosetta 
(DE3) cells. Constructs were either purified by Ni2+- or GSH-affinity chromatography 
separately. And eluted AIM2 constructs were then loaded to ASC or ASC-PYD immobilized 
on GSH-Sepharose resin. In addition, cell pellets containing either of the binding partners 
were mixed prior to cell lysis for co-purification by GSH-affinity chromatography only. 
Samples from co-expressions were also only purified by GSH-affinity chromatography. 
Purification steps were applied as described earlier (see chapter 2.1.8.3). Flow through, wash, 
loaded bead and elution fractions were analyzed by SDS PAGE and for better clarity 
immunostained after western blotting. 
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2.2.5.4. Western Blots and Immunostaining 
Protein samples from SDS PAGE gels were blotted to Nitrocellulose membranes (Roth, 
Karlsruhe, Germany) using a Blot® SD Semi-Dry Electrophoretic Transfer Cell from Biorad 
(Hercules, CA, USA) with transfer buffer containing 25 mM TRIS pH 8.6, 192 mM glycine, 
0.05 (w/v) % SDS, 20 % methanol at pH 9.2.  
For immunostaining, blots were rinsed several times in TBS-T (10mM TRIS pH 8.0, 
150mM NaCl, 0.01% Tween 20). Blots were then blocked against unspecific binding with a 
10 % (w/v) milk powder solution in TBS-T for one hour under continuous shaking and 
subsequently rinsed again. Membranes were probed by applying either a Horseradish 
Peroxidase (HRP) – coupled primary GST-antibody (GE Healthcare, 1:5000 in 2 % (w/v) 
milk powder solution in TBS-T) or both, a primary mouse His-antibody (1:2500) and 
subsequently a secondary HRP-coupled goat anti-mouse antibody (GE Healthcare, 1:5000)  
for one to two hours. 
Accordingly tagged protein was detected by adding the SuperSignal West Pico 
Chemiluminescent Substrate from Thermo Scientific (Bonn, Germany), subsequent exposure 
of the probed blots to a Hyperfilm™ ECL™ (GE Healthcare) and film development.    
 
2.2.6. Bioinformatic Methods 
2.2.6.1. Sequence Alignments 
Multiple sequence alignments were built with ClustalW2 
(http://www.ebi.ac.uk/Tools/clustalw2/) (Thompson et al. 2002) and visualized using ESPript 
(http://espript.ibcp.fr/ESPript/ESPript/). 
 
2.2.6.2. Calculation of Protein Parameters 
Physical and chemical parameters of the recombinant proteins such as molecular weight, 
theoretical isoelectric point (pI) and extinction coefficients were calculated with ProtParam 
(Wilkins et al. 1999) from the ExPASy Proteomics Server 
(www.expasy.org/tools/protparam.html). 
 
2.2.6.3. Structure Visualization and Analysis 
Structural visualization was achieved with PyMol (http://www.pymol.org) and 
electrostatic surfaces were calculated using the APBS plugin for PyMol (Baker et al. 2001). 
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Structures were superimposed for comparison using DaliLite (Holm et al. 2000). Structural 
conservation of single residues was assessed and visualized by ConSurf (Landau et al. 2005). 
 
2.2.6.4. Protein Profile Search 
Protein domains, patterns and profiles were identified using InterProScan at EBI 
(http://www.ebi.ac.uk/Tools/InterProScan/) and according structures were available through 
the protein data bank (PDB, http://www.pdb.org) of the Research Collaboratory for Structural 
Bioinformatics (RCSB). 
 
2.2.6.5. Structural Homology Modeling 
Comparative structural homology modeling was performed with MODELLER (Eswar et 
al. 2008) using the Bioinformatic Toolkit accessible online at http://toolkit.lmb.uni-
muenchen.de (Biegert et al. 2006). 
 
2.2.6.6. Secondary Structure Predictions 
RNA and DNA secondary structures were predicted with Mfold (http://mfold.bioinfo.rpi.edu/). 
Protein secondary structures were predicted based on sequence alignments with JPred 
(http://www.compbio.dundee.ac.uk/www-jpred/). 
 
2.2.7. Analytical Methods 
2.2.7.1. Mass Spectrometry 
Mass spectrometrical analysis of AIM2 degradation products was performed by the 
central protein analysis unit (ZfP) of the Ludwig-Maximilians-University München. Protein 
identification by MALDI peptide mass fingerprints was employed. 
 
2.2.7.2. Edman-Sequencing 
N-terminal degradation of AIM2 was analyzed by Edman-Sequencing at the protein 
analysis department of Prof. F. Lottspeich at the MPI of biochemistry (Martinsried, Germany) 
using standard methods. 
  
  LGP2 - Results 
41 
 
3. LGP2 – Results 
3.1. Full Length LGP2 
Full length (FL) LGP2 constructs harboring different tags were entirely insoluble when 
expressed in E. coli and so were helicase domain constructs. LGP2 could however be 
expressed in High Five insect cells. Still, only small amounts of soluble protein were obtained 
due to partial aggregation. Even in the presence of high salt concentrations during cell lysis 
the major fraction of LGP2 remained insoluble. Furthermore, purified LGP2 was rather prone 
to degradation (Fig. 9 A). Also preparations of LGP2 which has a pI around 7, using different 
buffers (pH 6, 7.5, 8.5) could neither improve protein yield nor stability. Purified LGP2 could 
not be highly concentrated (~ 1 mg/ml maximum), making crystallization setups impossible.  
Protein that had been stored at -80 °C as well as freshly prepared samples failed to 
exhibit any significant ATPase activity. Also an expected LGP2 dsRNA (25 bp or 40 bp) 
complex was not able to be detected by analytical gelfiltration. This might however be due to 
the protein’s instability. On the other hand electrophoretic mobility shift assays (EMSAs) 
(Fig. 9 B) could verify LGP2’s ability to bind double stranded RNA as previously 
hypothesized and as demonstrated for its regulatory domain (See chapter 3.2.). LGP2 is 
clearly retarding a 27 bp dsRNA in an EMSA, however the affinity of LGP2 to the labeled 
RNA seems to be low. Even with an approximately 17 times higher concentration of protein, 
there is still free RNA.  An explanation for the weak binding, apart from mentioned problems 
with LGP2 samples, might be sterical hindrance of binding caused by the fluorescence label 
on the 5’ end of the dsRNA. 
Figure 9 (A) Purified LGP2 sample (with N-terminal 6xHis-tag) from insect cell 
expression, analyzed on a 15 % SDS PAGE gel. (B) EMSA of a 27 bp Atto488 labeled 
dsRNA in presence of increasing concentrations of LGP2 analyzed on a 10 % native gel in a 
TB buffer system. 
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3.2. The Regulatory Domain of LGP2 
Full length LGP2 and helicase domain constructs proved to be too instable or insoluble 
and were not pursued further. The regulatory domain of LGP2 however emerged as an 
interesting target. The RD of RIG-I had been shown to be crucial for its nucleic acid sensing 
and signaling ability. It could be proposed that this might be also the case for LGP2 RD. 
Hence, gaining detailed knowledge of the molecular properties of LGP2 RD was supposed to 
help to explain the controversial regulatory effects LGP2 exhibits towards RIG-I and MDA5 
signaling.    
 
3.2.1. Constructs and Purification 
Constructs for the LGP2 RD were chosen according to sequence alignments with its 
homologs RIG-I and MDA5 (Figure 10), secondary structure predictions and the structure of 
RIG-I RD as guide for the domain boundary (PDB: 2QFD, 2QFB) (Cui et al. 2008). 
Constructs containing residues 543 - 678 (native C-terminus), 544 - 671, 549 - 678 or 537 - 
678 were expressed with different tags or without any tag in E. coli Rosetta cells and behaved 
similarly during purification. Due to its well established expression and purification protocol 
and highest solubility only the RD 537 - 678 construct expressed without tag was used for 
final crystallization setups, and the assays and mutational studies shown. Protein was purified 
from E. coli cell lysate using cation exchange and size exclusion chromatography. LGP2 RD 
was obtained in high purity but was prone to aggregation when concentrated higher than 
10 mg/ml. As an exception a concentration of 13 mg/ml could be reached for the construct 
containing residues 537 - 678 of LGP2 which was successfully crystallized. 
Point mutants of LGP2 RD 537-678 were obtained through site directed mutagenesis and 
were treated and behaved analogously to the wildtype construct. Only a mutation in the highly 
conserved Zn2+ coordination site, mutant C615A, resulted in an insoluble RD, likely due to 
compromised protein integrity. All mutated residues are listed and shown in Figures 10 and 
16. 
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Figure 10 Sequence alignment of RLR RDs with secondary structure annotation 
according to the LGP2 RD crystal structure. The four invariant Cys residues required for Zn2+ 
coordination are marked with asterisks. Identical residues are depicted in white and shaded in 
red, homolog residues are shown in red. Point mutated residues are marked with an M. 
  
3.2.2. Crystallization and Structure Determination of LGP2 RD 
Various LGP2 RD constructs were initially screened for crystallization using different 
screens, drop sizes and with and without addition of TCEP. However no crystals were 
obtained for most constructs. The condition that finally led to successful crystallization of 
LGP2 RD comprising residues 537 – 678 was derived from condition B2 of Jena Bioscience 
Classic screen II (2 M ammonium sulfate and 100 mM TRIS-HCl pH8.5). Initially, setups 
under this condition only resulted in crystalline precipitate in the screen and most refinements. 
Macrocrystals were grown by hanging drop vapor diffusion, with a 500 µl reservoir (1.5 M 
(NH4)2SO4, 100 mM TRIS pH8.5) and a drop size of 2 µl protein and 2 µl reservoir solution, 
after several weeks of incubation at 21°C. Crystals grew as clusters from the drop boundary 
but could be separated from each other (Fig. 11 A). Prior to cryo-protectant soaking and flash 
freezing in liquid nitrogen the crystals were soaked with mercury acetate in case molecular 
replacement would not be applicable and anomalous scattering would be required to allow for 
phasing. The best cryo-protection was achieved when soaking crystals in 2.5 M (NH4)2SO4 
and 100 mM TRIS-HCl pH 8.5. The final diffraction data was collected at the theoretical 
mercury absorption edge at a wavelength of 1.009 Å at ESRF beamline ID 14-4 (European 
synchrotron radiation facility, Grenoble, France).  
LGP2 RD crystallized in space group P212121 with four molecules per asymmetric unit. 
The crystals diffracted to 2.6 Å (Fig. 11 B) and an initial experimental electron density map 
revealing the localization of four mercury atoms could be obtained employing autoSHARP 
(Vonrhein et al. 2007) (Fig. 11 C). The actual structure could however be solved by molecular 
replacement with PHASER (McCoy et al. 2007b) using CHAINSAW (Stein 2008) adapted 
coordinates of RIG-I RD as search model. The four copies were initially refined with non-
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crystallographic symmetry restraints that were removed during final cycles of refinement. 
Parts of the experimental 2Fo-Fc electron density map and the final refined 2Fo-Fc electron 
density map after molecular replacement are shown in Figure 11 C and D. The obtained 
model spans residues 544 to 671, with the loop region between residues 593 and 601 not 
visible in the electron density map. The structure was refined to an R value of 22.7 (free R 
28.0) using Phenix and CNS (Adams et al. 2004; Brunger 2007) and its geometry is within 
normal parameters. Crystallographic data and statistics are summarized in Table 9.   
Figure 11 (A) Crystals of LGP2 RD comprising residues 537 - 678. (B) Diffraction 
pattern of LGP2 RD crystals to 2.6 Å. (C) Initial experimental 2Fo-Fc electron density map of 
LGP2 RD obtained by phasing using anomalous scattering of incorporated Hg2+ with 
autoSHARP. (D) Refined 2Fo-Fc electron density map of LGP2 RD acquired by molecular 
replacement with RIG-I RD. Electron densities are shown at a contour level of 1σ and only 
around some of the residues for better clarity. 
 
3.2.3. Overall Structure  
The regulatory domain of LGP2 is a globular, slightly flattened domain with a concave 
and convex side and dimensions of approximately 45 Å x 35 Å x 30 Å (Fig. 12 B). It is 
organized in three leaves, consisting of two four-stranded (β1, β2, β9, β10 and β5, β6, β7, β8) 
and one two-stranded (β3, β4) antiparallel β-sheet. Small 310 helical turns (η1 − η5) connect 
the three β-sheets. The C-terminus contains a short α-helix (α1). The loop connecting 
β5 and β6 is partially undefined in the crystal structure of LGP2 RD.  This and the high B 
factors apparent for residues at the base of the loop indicate increased flexibility in this 
region.  
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Table 9 Crystallographic Data and Refinement Statistics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The four-stranded β-sheets are laterally connected by two protruding loops, each 
containing two highly conserved cysteine residues (C556 and C559; C612 and C615). Together, 
the four thiol groups of these cysteines coordinate a mercury ion in each of the four molecules 
in the asymmetric unit (Fig. 12 A, B). Based on the RIG-I RD structure and in accordance 
with the stability of LGP2 RD in ZnCl2 supplemented buffers, Zn2+ can be assumed to be the 
physiologically coordinated metal ion in LGP2 RD. It has however been replaced by Hg2+ in 
the structure due to the exposure of the crystals to a high Hg2+ concentration.  
Data collection  
Space group P212121 
Cell dimensions  
a, b, c (Å) a=63.67 
b=75.63 
c= 147.87 
α, β, γ (°) 90, 90, 90 
Wavelength (Å) 1.009 
Resolution (Å) 50 – 2.6 (2.75 – 2.6) a   
Reflectionsobserved 105887 
Reflectionsunique 41141 
Rsym  5.6 (29.3) 
I / σI 13.68 (3.58) 
Completeness (%) 92.8 (85.7) 
Refinement  
Resolution (Å) 48.0 – 2.6 
No. reflections 22420 / 1088 
Rwork / Rfree 22.7 / 28.0 
No. atoms  
Protein 3854 
Hg2+ 4 
SO42- 5 
Water 248 
B-factors  
Protein 36.1 
R.m.s deviations  
Bond lengths (Å) 0.01 
Bond angles (°) 1.26 
Ramachandran statistics (%) 
most favored 89.4 
additionally allowed   9.9 
generously allowed   0.7 
aHighest resolution shell is shown in parentheses. 
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Figure 12 (A) Shows the Zn2+ (respectively Hg2+) coordination by a 4 Cys cluster in 
LGP2 RD with the refined 2Fo-Fc electron density map at 1σ.  A stereo cartoon representation 
of the tertiary crystal structure of LGP2 is depicted in (B). 
 
The concave part of the LGP2 RD is highly positively charged implicating the presence 
of an RNA binding site similar to RIG-I RD. 
Two sulfate ions were found to be coordinated on the convex site of the molecule. Even 
though the RNA binding site is most likely to be located on the opposite, concave region of 
LGP2 RD these sulfate ions might resemble a second binding moiety with the sulfates 
mimicking RNA backbone phosphates (Fig. 13). However there is no experimental evidence 
for this and mutations in this region (N853D) did not alter RNA interaction (see chapter 3.2.6).  
 
Figure 13 (A) Refined 2Fo-Fc electron density map representation of the two sulfate 
molecules found coordinated in the LGP2 RD crystal structure and neighboring amino acid 
side chains. Opposite this coordination site K634 that is located in the center of the positively 
charged cleft is highlighted. (B) Location of the two sulfate ions in a little conserved region 
opposite the positively charged proposed RNA binding cleft.   
  LGP2 - Results 
47 
 
3.2.4. Comparison of LGP2 RD to RIG-I and MDA5 RDs 
With the exception of some differences in loop regions that connect secondary structure, 
the overall fold of LGP2 RD is highly related to that of RIG-I and MDA5 RDs (Fig. 14 A). In 
particular, the backbone geometry of the metal ion coordinating cluster is highly conserved 
between RIG-I, MDA5 and LGP2 (Fig. 14 A). The metal in LGP2 is coordinated in a 
tetrahedral manner by the sulfur atoms of the cysteine cluster C556, C559, C612 and C615. 
Although a mercury ion is found in this crystal form the geometry should be similar in the 
presence of Zn2+, since crystal structures of RIG-I RD in the presence of mercury and zinc 
ions have a virtually identical conformation (Cui et al. 2008).  
Figure 14 (A) Superposition of the entire RD of LGP2 (green, black, grey) and RIG-I 
(pale orange) with the Cys cluster and putative RNA binding sites highlighted. Inset: close up 
view of the superposition of the Zn2+ (Hg2+)-coordination sites of all three RLR RDs (RIG-I: 
pale orange, MDA5: yellow, LGP2: grey loops/green sheets). (B+C) Positively charged 
putative RNA binding clefts of LGP2 (B) and RIG-I RD (C). Conserved W619/873 that bounds 
the 4-Cys cluster towards the domain core, L634/888 and H576/830 residues are shown in stick 
representation. Electrostatic surface charge potential ranges from -5 kT (red) to 5 kT (blue). 
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Tryptophan619LGP2 – conserved between LGP2, RIG-I and MDA5 – bounds the Cys-
cluster towards the core of the domain (Fig. 14 B, C). Thus, correct formation of the metal 
coordination sphere is likely to be essential for the fold and integrity of RDs. In support of 
this, point mutation of the metal coordinating C615LGP2 to an alanine resulted in an unstable 
LGP2 RD, which was insolubly expressed in E. coli. Also the severe effect of cysteine point 
mutations in the zinc-binding cluster on signaling activity of RIG-I (Cui et al. 2008) and 
LGP2 (Pippig et al. 2009) correlates with this.  
A notable difference in the metal binding site between RIG-I, MDA5 and LGP2 RD is 
the loop, which connects C612LGP2 and C615LGP2. In RIG-I this loop is two residues longer than 
in LGP2, forming a short β-turn. In contrast, for MDA5 this loop is one amino acid shorter 
than in LGP2. This indicates that this region could account for functional differences between 
RIG-I like helicases (Fig. 14 A). 
The regulatory domain of RIG-I was shown to specifically bind to RNA with 5’-
triphosphates and is suggested to be a main sensor site for 5’-triphosphate containing viral 
RNA. Key residues important for RIG-I RNA binding were mapped to a groove formed at the 
interface of the four- and two-stranded β-sheets. These include several lysines as well as a 
histidine, residues which are well suited to bind to the RNA backbone and the 5’-triphosphate 
moiety. Intriguingly, two of these residues, K888RIG-I and H830RIG-I are conserved in LGP2 
(K634LGP2 and H576LGP2, respectively), indicating that this region could also be an important 
functional site of LGP2 (Fig. 14 B, C).  
Furthermore, in LGP2 RD, the groove carries a similarly pronounced positive 
electrostatic potential that would be ideal for RNA backbone interaction (Fig. 14 B, C). 
Additionally, this area is flanked by two conserved 310 turns (η4 and η5), which are possible 
phosphate recognition sites (Fig. 12 B).  
The positively charged cleft of RLR RDs exhibits much higher sequence conservation 
amongst homologs than the rest of the molecule (Fig. 15). Thus, this area is very likely a 
common RNA binding site in RLRs, whereas the unconserved site of the molecule could 
confer the unique regulatory mode of action of LGP2. 
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Figure 15 Single residue conservation in RLR RDs is shown in the LGP2 structure with a 
representation of the surface charge potential (-5 kT red to 5 kT blue) in comparison to a 
surface representation with invariant residues depicted as purple areas. The conserved Cys 
cluster is shown in cartoon representation for orientation. 
 
Figure 16 (A) Comparison of the unconserved area of residues around K858RIG-I, found to 
be essential for 5’-triphophate RNA interaction in RIG-I, by superposition of RIG-I (pale 
orange) and LGP2 RD (green, black, grey) structures. (B) Point mutated residues for RNA 
binding studies and their location in LGP2 RD (H576Y, N583D, W604A, K605E, P606K, C615A, L621A, 
K626E and K634E). Electrostatic surface potential is shown for orientation and ranges from -8 
kT (red) to 8 kT (blue). 
 
Despite the high similarity of RIG-I and LGP2 RD at initial inspection, some important 
structural differences arise. RIG-I’s K858 has for example been shown to be essential for
5’-triphosphate RNA interactions. However this residue is not conserved in LGP2 and is 
replaced by a proline in this position (P606, Fig. 16). 
Interestingly, some of these crucial but variable residues are directly adjacent to the 
flexible loop region between β-sheets 5 and 6. This loop seems to shield the variable residues 
located in β6 towards the surface. Hence, LGP2 is not entirely structurally conserved 
concerning residues shown important for RIG-I activity and RNA affinity. It is therefore 
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probable that while the general RNA binding area is the same amongst RD domains of the 
RIG-I like family, minor differences in certain residues confer different specificities towards 
distinct RNA types.  
Based on this, the region around LGP2 P606 with the adjacent loop between β5 and β6 
(Fig. 12, 16) was proposed to confer specificity in RNA binding. Residues to be mutated in 
order to test this hypothesis were chosen according to the electrostatic surface potential of 
LGP2 RD and based on the RIG-I RD structure, as well as sequence alignments and 
previously conducted mutant studies of RIG-I.  
Point mutations were introduced for residues homolog to those in positions found crucial 
for RNA interaction of RIG-I RD (H830  H576Y, K858  P606K, I875  L621A and K888  
K634E). Further point mutants were produced for the immediate neighbors of P606 (F856  
W604A, E857  K605E). Another mutation was introduced outside the positively charged cleft in 
proximity to the identified SO42- ions, A837  N583D, to examine whether this area is 
functionally important. Furthermore, a conserved Lys outside the putative RNA binding cleft 
K880  K626E and a Cys in the Zn2+ binding site, to prove the cluster’s importance for protein 
integrity and function among the RLR group (C869  C615A), were mutated. Residues were 
either exchanged to uncharged alanines or to inversely charged amino acids, like Glu for Lys. 
P606 was mutated to a Lys, which is found in RIG-I RD in this position. 
 
3.2.5. LGP2 RD Binds to dsRNA in a 5’-Triphosphate Independent Manner 
To learn more about the functional sites of LGP2 RD, its binding to different RNA 
structures was examined. The physiological ligand for LGP2 is unclear; however it has been 
shown to prefer to bind dsRNA over ssRNA (Murali et al. 2008). Its negative regulation of 
RIG-I dependent signaling in vivo may result from competition for viral RNA and thus could 
be directed against two RIG-I PAMPs, 5’-triphosphate RNA and dsRNA.  
According to the findings for RIG-I RD it seemed likely that RD of LGP2 also represents 
an RNA recognizing element. To confirm this hypothesis RNA oligonucleotides were tested 
for binding to LGP2 RD in equilibrium binding experiments using fluorescence polarization 
anisotropy measurements. LGP2 RD was found to bind to a 25mer dsRNA with high affinity 
and an apparent Kd of 68 ± 6 nM (see also chapter 3.2.6 and Fig. 18). 
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Furthermore binding to other RNA species was analyzed by means of competition 
experiments (Fig. 17). Thereby, a fluorescently labeled dsRNA hairpin was titered away from 
LGP2 RD by increasing amounts of unlabelled ssRNA or dsRNA ligands bearing or lacking 
5’-triphosphates. 5’-OH ssRNA, corresponding in length and sequence to the labeled probe, is 
a poor competitor, indicating that LGP2 RD does not efficiently bind to ssRNA. On the other 
hand, 5’-OH dsRNA with blunt ends is an efficient competitor. Since dsRNA with two blunt 
ends binds more efficiently than a 5’-triphosphate hairpin with a similarly long stem region, it 
is likely that certain RNA end structures could enhance specific dsRNA binding by LGP2 
RD. 
 
Figure 17 Competition of binding of an AlexaFluor 488-5-U labeled hairpin RNA (in 
vitro transcribed, 40 nM) to LGP2 RD (470 nM) by stepwise addition of different non-
fluorescent RNA species (synthetic 5’OH/5’OH dsRNA, 5’PPP/5’OH dsRNA, 5’OH ssRNA, 
5’PPP ssRNA and in vitro transcribed 5’PPP hairpin) followed by fluorescence anisotropy.  
Data points were connected for better outline. 
 
To determine whether 5’-triphosphate is equally important for LGP2 RD - RNA 
interaction as for RIG-I RD, single and double strand RNA oligonucleotides harboring a 
5’-triphosphate were tested for competition. However, no substantial difference in 
binding of LGP2 RD to the corresponding RNAs with 5’-triphosphate compared to those 
without was measured.  
This contrasts to the 5’-triphosphate dependence of RNA binding by RIG-I RD. Taken 
together; it appears that RD is an important element in specific dsRNA recognition by LGP2 
and that 5’-triphosphates are not central epitopes recognized by LGP2 RD.
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3.2.6. The dsRNA Binding Site of LGP2 
To specify and characterize the exact RNA binding site of LGP2 RD, previously 
mentioned point mutations were introduced inside and outside the positively charged cleft that 
was predicted to be the RNA interacting area (Fig. 16 B).    
RNA binding of the wildtype and mutant RD variants was analyzed by fluorescence 
anisotropy (Fig. 18). Even though it was not entirely clear how many RD binding sites exist 
on the RNA strands used for anisotropy measurements, the binding isotherm was fitted with a 
single site-binding model. This was done for reasons of simplification, after trying to fit the 
data with different binding models and finding that all yield nearly invariant apparent Kd 
values. 
 
Figure 18 Binding of dsRNA to LGP2 RD. (A) Fluorescence anisotropy changes of a 
5’-AlexaFluor 488 labeled 25 bp RNA duplex (37 nM) in response to titration with wildtype 
(wt) LGP2 RD (filled square, Kd = 68 ± 6 nM) and various mutants, respectively. Control 
mutation N583D (open diamond, Kd = 38 ± 4 nM), located on the convex site of RD and 
mutation K626E (open left-facing triangle, Kd = 51 ± 5 nM) do not show significantly altered 
dsRNA binding affinity. Affinities for mutants L621A (filled up-facing triangle, Kd = 165 ± 
26 nM) and K605E (filled down-facing triangle, Kd = 140 ± 16 nM) are slightly decreased, 
while a mutation of K634E (filled circle) completely suppresses binding. A decrease of binding 
affinity, but increase in maximum reached anisotropy signal is seen for P606K (open right-
facing triangle, Kd = 230 ± 10 nM), W604A (open square, Kd = 136 ± 6 nM) and H576Y (open 
circle, Kd = 304 ± 10 nM).  
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3.2.6.1. Study of LGP2 RD’s RNA Interaction by Fluorescence Anisotropy 
Comparing the obtained results between mutants and wildtype RD it becomes obvious 
that mutations in the concave, positively charged surface patch (K634E, L621A, K605E, P606K, 
W604A, H576Y) generally affect RNA binding, while mutations outside this region (N583D, 
K626E) do not confer any evident alteration in the RNA binding behavior of LGP2 RD. Thus, 
there is no involvement in RNA binding of the area where SO42- ions are coordinated in the 
LGP2 RD crystal structure. 
Point mutation of K634E completely abolished RNA binding of LGP2 RD. This residue is 
conserved between RIG-I like helicases and situated at the N-terminus of a 310 turn (η4) at the 
center of the concave surface. The equivalent mutation in RIG-I K888E also had a severe effect 
on RIG-I’s RNA interaction and activity (Cui et al. 2008).  
The conservation of this lysine residue in different RDs with evidently different RNA 
specificities (5’-triphosphate in RIG-I versus dsRNA in LGP2) argues that this site is not 
involved in distinguishing different RNA epitopes, but more likely is a central core RNA 
interaction site shared by all three RDs. 
The mutant P606K still binds RNA with reasonable efficiency, which might be due to the 
replacement with a positively charged residue, while the corresponding K858A mutation 
severely reduced 5’-triphosphate RNA binding of RIG-I RD and abolished RIG-I activity in 
vivo. Other mutations of LGP2 RD in the same region (H576Y, W604A) also bind RNA with 
reasonable, albeit reduced affinity (Fig. 18). Interestingly, although Kd values for dsRNA 
binding by these three mutants are slightly lower than for wildtype RD, much higher 
anisotropy changes are measured compared to the wild type RD. This indicates that the 
RNA/protein complexes formed by these mutant RD variants are larger than those obtained 
for wild type RD. This could be due to the fact that these mutant proteins might oligomerize 
upon binding to RNA. However, such a gain of function by only one single residue change 
seems unlikely. Another explanation is that these particular mutants can bind simultaneously 
at multiple sites on the RNA, while the wildtype binds more specifically to only one or a few 
distinct sites. 
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3.2.6.2. Electrophoretic Mobility Shift Assays of LGP2 RD – RNA complexes 
EMSAs with wild type and mutant LGP2 RDs were conducted, to further investigate the 
divergence of their dsRNA binding affinity and specificity, (Fig. 19). In general, the EMSAs 
confirm the results of the anisotropy measurements with respect to altered or retained dsRNA 
binding of specific mutants (Fig. 19 A). Concentration dependent analysis indicates that wild 
type RD indeed shifts dsRNA to defined, specific bands. An initial shifted species with higher 
mobility is subsequently converted into a species with lower mobility (Fig. 19 B). 
 
Figure 19  Electrophoretic mobility shift assays of LGP2 RD and mutants with dsRNA. 
(A) Retardation of 5’-AlexaFluor 488 labeled dsRNA (25 bp, 60 nM) in a 10% native 
polyacrylamide gel after incubation with 400 nM wt LGP2 RD or indicated RD mutants, 
respectively. (B) Retardation of 5’-AlexaFluor 488 labeled dsRNA (25 bp, 60 nM) in a 10 % 
native polyacrylamide gel after incubation with increasing concentrations (0, 0.4, 0.8, 1.6, 3.2, 
6.4 µM) of wt LGP2 RD and mutants P606K, W604A and H576Y. 
 
These data suggest that two LGP2 RD molecules can bind to the dsRNA ligand. One 
possibility is that RD specifically forms dimers on a single site on the dsRNA substrate. 
Another option is that two binding sites for LPG2 RD exist on the RNA. Since LGP2 RD 
exhibits higher affinity to dsRNA than to an RNA hairpin of the same concentration and 
similar stem length, another explanation is that RNA end structures contribute to binding. 
Hence, the two EMSA species would be corresponding complexes with either one or both 
RNA ends masked by protein. In any case, the observed species in the EMSAs are well 
defined, indicating a particularly specific interaction of LGP2 RD with the dsRNA substrate. 
Mutant K634E entirely fails to interact with the RNA double strand. Also the distinct 
bands found for the wildtype RD - RNA complex are lost for the H576Y, W604A and P606K 
mutants of RD (Fig. 19 B). Instead, an unspecific distribution (“smear”) of slower migrating 
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complexes can be observed. Aside from the unspecific shifting, the mutants also exhibit lower 
affinity to the RNA compared to wt RD, indicated by remaining free dsRNA bands for all 
protein concentrations. 
These mutations do not seem to disrupt RNA binding per se, but lower the affinity and 
possibly lead to a more distributed unspecific binding all along the RNA duplex. These 
mutant RDs could bind indiscriminately to many possible binding sites on the dsRNA ligand, 
perhaps also as multimers at higher protein concentrations, which could account for the larger 
complexes observed in both EMSA and fluorescence anisotropy measurements. Taken 
together, these data argue that the residues around P606 form the specificity site of LGP2 RD. 
 
3.3. RD – RNA Complex Crystallization Attempts 
3.3.1. Generation of 5’-Triphosphate RNAs for Co-crystallization with RIG-I RD 
In addition to the analysis of LGP2, RNA ligands suited for co-crystallization with 
RIG-I RD should be established and tested for complex formation and crystallization. At this 
point a physiological ligand of RIG-I was believed to be 5’-triphosphate ssRNA, despite the 
helicase domain showing a preference for dsRNA. RIG-I RD had been shown to be the 
5’-triphosphate sensor with the binding site being mapped to a positively charged groove on 
the concave site of the molecule (Cui et al. 2008) analog as described for LGP2 RD. 
Since no protocols were available for efficient synthesis of 5’-triphosphate containing 
RNA in quantities large enough for crystallization, in vitro transcription had to be employed 
to generate the 5’-triphosphate ligands. This was achieved by either using recombinant T7 
RNA-Polymerase purified in the lab or the Ambion Megashort Transcript kit, which is 
especially suited for the transcription of the short RNAs that would be required for optimal 
crystal packing in co-crystallization setups.  
Initially, a 58mer of the rabies virus leader (RVL) sequence was produced, according to 
the one used in former RIG-I RNA binding studies, and tested in analytical gelfiltration 
experiments for binding to either LGP2 or RIG-I RD. Surprisingly, and despite its 
demonstrated preference for dsRNA, LGP2 RD formed a stable complex with the single-
stranded 5’-triphosphate containing 58 nt RVL comparable to RIG-I RD (Fig. 20 A, B). Since 
the binding was almost as strong as for RIG-I RD, but with LGP2 RD known to exhibit only 
weak binding towards ssRNA, it could be assumed, that the in vitro transcribed sample did 
not solely contain ssRNA, but possibly also some double strand species or duplex regions. 
This can result from “back-looping” of the T7 RNA Polymerase when reaching the end of the 
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template strand rather than producing run-off ssRNA products and RNA-template primed 
RNA synthesis (Cazenave et al. 1994; Arnaud-Barbe et al. 1998). Despite the possible 
inhomogeneity of the RNA, a rather distinct additional, early eluting peak appeared on the 
elution profile of the gelfiltration for both proteins, suggesting formation of a protein-RNA 
complex. The number of binding sites on the 58 nt RVL remains unclear for both RDs, with 
calculated values ranging between 1.3 and 1.7 molecules per RNA molecule, according to the 
molecular weight standard. Also there is no evidence for possible dimerization of RDs. 
Furthermore, complex formation with an in vitro transcribed ribozyme product with 159 nt 
was analyzed and showed similar results, whereas incubation of RDs with either synthetic Na-
triphosphate or a PolyA octamer failed to induce detectable complexes (not shown). 
 
 
Figure 20 In vitro transcribed RNA (58mer RV leader) forms stable complexes with 
either LGP2 RD (A) or RIG-I RD (B) that are detectable in analytical gelfiltration. 
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In order to co-crystallize RIG-I RD, shorter RNAs were required, since long uncoated 
RNA overhangs were assumed to disturb proper crystal packing. Therefore, 5’-triphosphate 
RNAs with a length around 6 – 21 nucleotides were targeted. Various transcription strategies 
are shown in Fig. 21.  
Figure 21 Strategies to obtain short 5’-triphosphate RNAs with homogeneous 3’ ends. 
(A) Secondary structure of a modified HDV ribozyme used. (B) 6M urea/ 12 % (w/v) 
polyacrylamide gel with increasing yield of 159 nt ribozyme cleavage products after 6h 
incubation at 37 °C of run-off in vitro transcription products obtained with different template 
concentrations. In comparison ribozyme constructs containing 21, 12 or 9 nt do not appear 
cleaved. (C) Scheme of a DNAzyme and (D) Transcription termination by incorporation of 
ddNTPs, such as ddUTP. 
 
Initially ribozyme and DNAzyme mediated generation of in vitro transcribed RNA 
harboring homogenous 3’ ends was tested (Fig. 21 C, D). Run-off transcription of long RNA 
strands is much more efficient than transcription of short targets. This is due to the T7 
polymerase’s improved initiation and activity on longer template strands. The longer the 
template, the less premature termination of transcription, usually after the first 2 to 12 
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nucleotides, occurs. Ribozymes and DNAzymes represent practical tools for obtaining short 
homogenous RNAs from initially long in vitro transcribed strands. In case of the first, the 
shortness of the sequence to be autocatalytically cleaved off appeared to diminish the 
efficiency of the reaction. Different from a 159 nt sequence initially used for optimization of 
reaction conditions, insertions of 9, 12 or 21 nucleotides in front of the ribozyme did not yield 
homogeneous cleavage products (Fig. 21 B). For the DNAzyme, discrimination between and 
separation of the DNA and the RNA product and reaction yield proved to be a bottleneck. 
As another strategy transcription has been conducted using long templates, but by trying 
to force synthesis of more abortive short RNA products by using AlexaFluor-labeled UTP, 
that might potentially promote polymerization stop. This does not necessarily produce a 
homogeneous product though. A definite polymerization break was achieved by adding 
dideoxy-UTP instead of normal UTP to the reaction mixture, preventing any further 
elongation after the first introduced ddUTP. However, the obtained products can still contain 
a mix of even shorter RNA products if polymerization stops short of the site of ddUTP 
incorporation. 
Even though transcription products were tried to be purified by reversed phase 
chromatography, samples were usually too dilute and inhomogeneous to yield significant 
amounts of pure RNA. Furthermore, the inherent proneness of T7 Polymerase and especially 
the non-commercial one, to early abortion of transcription, leads to a mix of different aborted 
RNAs between 2 and 12 nucleotides, making targets in the same range hard to purify. Also 
integration of up to four Gs that are favorable for transcription efficiency at the beginning of 
the transcript could not significantly improve yields. 
Nevertheless, RIG-I RD was able to bind transcription products with incorporated 
AlexaFluor-UTP or ddUTP, forming a stable complex that could be detected and separated by 
preparative gelfiltration (Fig. 22). Thus, selection and hence homogeneity of the RNA ligand 
by RIG-I RD was potentially achieved. 
Incubation of RIG-I RD with those RNAs resulted in quantitative complex formation. 
Comparing the gelfiltration retention volumes of RIG-I RD by itself, residual free RNA 
oligonucleotide and RIG-I RD in complex with RNA to a molecular weight standard, the 
complex appears about twice as large compared to RIG-I RD alone. This suggests that two 
RD molecules specifically interact with the in vitro transcribed RNA constructs, possibly via 
the RNA ends as proposed for LGP2 RD. This is speculative, since an exact prediction of the 
properties of the RNA ligand cannot be made and it is not clear that it really is only the 
expected short single strand.    
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Figure 22 Elution profile of RIG-I RD by itself (solid black line) and in complex with 
AlexaFluor 488-UTP (dark dotted line) or ddUTP (light dashed line) incorporated RNA from 
a preparative Superdex S75 26/60 gelfiltration. A: aggregate, O: free RNA oligonucleotide 
(apparent molecular weight – MW~1.3 kDa), R: RIG-I RD only (MW~15 kDa), C: Complex 
of RIG-I RD and RNA (MW~36 kDa). 
 
3.3.2. Co-crystallization of RIG-I RD with 5’-Triphosphate RNA 
RIG-I RD – RNA complexes were purified by gelfiltration and subsequently screened for 
crystallization. The best shaped crystals were obtained with the ddUTP-transcript containing 
samples. Initial screens yielded mainly needles, generally in various conditions containing 
PEGs and Lithium-salts. Crystals were grown at 4 °C to ensure RNA stability and could be 
refined to 3-dimensional rods after macro seeding (Fig. 23).  
 
Figure 23 RIG-I RD/RNA complex crystals grown in 100 mM TRIS HCl pH 8.5, 18% 
(w/v) PEG 8000, 200 mM Li2SO4 in Jena Bioscience Classic HTSL Screen I and after 
refinement. 
 
  
  LGP2 - Results 
60 
 
Unfortunately, all crystals showed weak diffraction (maximum 8 Å) or none at all. It is 
possible that the RNA quality and homogeneity was not high enough to ensure proper crystal 
packing and order. The chosen RNA ligand lengths could further not be ideal. Also, the single 
stranded character of the used RNA ligands might have been disadvantageous, given that later 
on RIG-I RD became known to actually prefer blunt end double strand RNA containing a 
5’-triphosphate as a ligand. 
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4. AIM2 – Results 
4.1. Full Length Mouse AIM2 
4.1.1. Identification and Purification of Degradation Products of mAIM2 
Since human full length AIM2 was prone to aggregation when expressed in E. coli, the 
much better behaving mouse homolog was used for structural and functional studies of AIM2. 
It will be further on referred to as mAIM2. First attempts to purify mAIM2 with an N-terminal 
Hexa-His-tag failed due to the protein not binding to Ni-NTA, indicating either inaccessibility 
of the tag or N-terminal degradation. mAIM2 could be purified carrying a C-terminal 6xHis-
tag or without any tag using Heparin affinity chromatography. The purified protein always 
exhibited a smaller apparent molecular weight on SDS-PAGE gels than expected and 
degradation products were detected that could not be resolved by gelfiltration 
chromatography. The best separation of the degraded AIM2 fragments was achieved by cation 
exchange chromatography (Fig. 24). Without affinity tag, mAIM2 has a theoretical molecular 
weight of 40.2 kDa. Purified AIM2 fragments exhibit apparent molecular weights of 34 kDa 
and 37 kDa according to migration in SDS PAGE. To identify the degradation products of 
untagged mAIM2, samples have been analyzed by mass spectrometry after isolation from 
distinct SDS PAGE gel bands and tryptic digest. This analysis showed that both major 
purification products referred to mAIM2 and that mainly peptide patterns from the N-terminal 
region were missing in the spectra, also supporting the idea of N-terminal degradation of the 
protein. 
Figure 24 SDS PAGE gel of samples from elution fractions of mAIM2 from an SP-
Sepharose column run as final purification step. Both major bands migrating around 37 and 
34 kDa correspond to mAIM2 according to mass spectrometric analysis (analyzed bands are 
framed in red). 
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To finally prove this and determine the exact constructs, Edman sequencing was 
performed for the two most abundant degradation products. Cleavage sites were identified in 
either the Pyrin domain (residues 1-90, e.g. M75) or between the Pyrin and HIN domain in an 
unstructured region (see chapter 4.1.2, residue T94). Theoretical molecular weights of the 
corresponding degradation products are even lower than the apparent ones on SDS PAGE. 
 
4.1.2. Structural Model of AIM2 
In absence of a stable full length mAIM2 crystallization target structural modeling has 
been performed. As verified by various pattern and motive search programs AIM2 was found 
to contain an N-terminal death domain fold Pyrin (or PAAD/DAPIN) domain (PYD, res 1- 
90) and a C-terminal HIN-200 (or IF120x) domain (res 140 – 354). Sequence alignments were 
performed separately for the domains (Fig. 25). Through the PFAM database, homolog 
domains with known 3D structures were identified and best matches for each domain were 
then used to model the tertiary structure of mAIM2 with Modeller (Fig. 26 A). For the DNA 
binding HIN domain the two HIN domains of human Gamma-Interferon-Inducible Protein 16 
(Ifi16, PDB: 2OQ0, 3B6Y) exhibit high homology with sequence identities over 40% (Fig. 25 
B). Both structures were used for AIM2 modeling. Pyrin domains of AIM2 are not as highly 
homologous to other Pyrin domains such as PYD of hASC, human and mouse NACHT-, 
LRR- and PYD-containing protein (hNALP1 and mNALP10, part of NALP inflammasomes), 
human Myeloid cell nuclear differentiation antigen (hMNDA) and mouse Interferon-Inducible 
Protein  205 (mIfi205), for which structures are available (Fig. 25 A). Modeling was 
performed based on the mNALP10 (PDB: 2DO9) PYD structure that shows highest 
similarity, amongst the candidates, to the mAIM2 PYD with a sequence identity of ~25%.   
The region between the Pyrin and HIN domain of mAIM2 could not be reliably modeled 
due to a lack of homology models and as it does not belong to a distinct domain. Secondary 
structure predictions indicate that this region is unstructured (Fig. 25 C). Sheets and helices 
predicted by various algorithms (like JPred and PSIPred) in this area have a much lower 
probability or prediction confidence than nearby structural elements.  
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Figure 25 Multiple sequence alignments of (A) the m/hAIM2 Pyrin domain with homolog 
PYD domains with known 3D structures and (B) the m/hAIM2 HIN-200 domain with the two 
HIN domains of human Ifi16 (PDB: 2OQ0, 3B6Y) used for building a tertiary structure 
model of mAIM2. (C) Secondary structure prediction of the unstructured region between PYD 
and HIN in AIM2 with decreasing color intensities correlating with low prediction 
confidence.  
 
The modeled HIN-200 domain exhibits a large positively charged cleft between the two 
characteristic OB folds that appears suited to bind DNA (Fig. 26 A) 
As expected, the predicted PYD fold of mAIM2 is very similar to ASC PYD. However, it 
exhibits a quite different modeled electrostatic surface potential (Fig. 26 B). PYD in mAIM2 
is mainly required for hetero interactions with for example ASC PYD. In addition it may be 
involved in AIM2 oligomerization, as has been shown for ASC.  
 
 
 
A 
B 
C 
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Figure 26 Structural model of (A) mAIM2 with the N-terminal Pyrin domain on the right 
and the C-terminal HIN domain depicted on the left, connected by a flexible linker region. 
The tentative electrostatic potential ranges from -5 kT (red) to 5 kT (blue) and a dsDNA has 
been docked to a positively charged groove between the two conserved OB-folds of the HIN 
domain. In comparison (B) shows the experimentally solved structure of the ASC-Pyrin 
domain (PDB: 2KN6) harboring the same death domain fold as the modeled AIM2-PYD. 
 
4.2. The AIM2 HIN Domain 
Since the Pyrin domain of AIM2 is prone to degradation, and therefore difficult to work 
with, the DNA-binding HIN domain by itself was focused on for structural and functional 
characterization. 
HIN constructs were chosen according to sequence alignments, fold predictions, mass 
spectrometric results from degradation products of full length AIM2 preparations that suggest 
an N-terminal degradation and based on Edman sequencing results also from degradation 
products. Constructs used are hAIM2 140-343, mAIM2 146-354, mAIM2 94-354 and mAIM2 
137-354. 
The HIN domain of human AIM2 containing residues 140 – 343 (native C-terminus) 
could be expressed in soluble form with an N-terminal Hexa-His-tag in E. coli Rosetta (DE3) 
cells, yielding ~35 mg protein from a 4.5 l expression. Removal of endogenous DNA bound 
to the HIN-domain was achieved by a 2M NaCl high salt wash of the protein while 
immobilized on Ni-NTA. Crystallization screens of the purified construct without DNA did 
not result in any hits and addition of stoichiometric amounts of DNA resulted in immediate 
precipitation of the protein. EMSAs with quite small amounts of DNA could show binding of 
the HIN domain to dsDNA, however in a weak, unspecific manner, possibly caused by the 
constructs proneness to aggregation in the presence of DNA (not shown). 
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The HIN domain of mouse AIM2 (residues 146-354) could be purified similarly and 
appeared more stable. After removal of the His-tag the construct was less prone to 
aggregation when incubated with DNA. Since HIN constructs generally seemed to be more 
stable after removal of the His-tag, new constructs (AIM2-HIN: 146-354, 94-354, 137-354) 
were cloned and purified without any tag. Sufficient purity of the DNA-binding constructs 
was thereby achieved by purification using Heparin affinity, cation exchange and size 
exclusion chromatography.   
 
4.3. Evaluation of mAIM2 – DNA Complex Formation by Electrophoretic Mobility Shift 
Assays 
To evaluate mAIM2 binding to short DNAs and the contribution of the HIN domain 
EMSAs have been carried out using “full length” mAIM2 (protein corresponding to the 
sample with lowest mobility in SDS PAGE from the preparation of the full length construct) 
and the HIN domain construct mAIM2 146-354 (Fig. 27). Two different DNA lengths and 
topologies were tested for binding, an 11 bp + 4 nt hairpin and a 35 bp DNA double strand.  
The 11 bp hairpin can accommodate binding of two HIN domain molecules as can be 
seen by the successive appearance of two distinct bands with lower mobility than DNA itself 
in the EMSAs. For the longer AIM2 construct there seems to be only one binding site on this 
short DNA, judging from one lower mobility band appearing with higher protein 
concentrations. This is likely due to steric or spatial constriction. With increasing AIM2 
concentration the entire sample does not migrate into the gel, which might be due to 
formation of higher oligomeric assemblies or just unspecific aggregates that are above the 
molecular cutoff of the gel matrix (Fig. 27 A). This was also observed for the longer DNA 
construct. Furthermore it seems that the 35 bp DNA can facilitate binding of two molecules of 
either the HIN domain or also the “full length” construct, resulting in two distinctly shifted 
bands (Fig. 27 B). Binding affinities can only be estimated from the EMSAs but seem rather 
high. The apparent Kd is around 100 nM and even though the number of molecules bound to 
the different DNAs varies, affinities appear to be similar.  
  It should be noted that although the fast annealing procedure (5 min at 95°C then 
immediate storage on ice) used for the hairpin DNA should ensure a proper hairpin formation, 
a self-annealing of the 26 nt DNA that would result in a 26 bp dsDNA rather than the 11 bp 
hairpin, cannot be entirely ruled out. Hence, no reliable conclusion concerning the minimum 
dsDNA length required for AIM2 or only HIN domain binding can be derived.  
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Figure 27 Electrophoretic mobility shift assays of mAIM2 full length (theoretically) and 
HIN (146-354) domain constructs studying binding to (A) a DNA hairpin with 11 bp stem 
and a tetraloop labeled with 3’-FAM or (B) a 35bp annealed dsDNA containing 5’-ATTO488 
as fluorescent label. Protein concentration steps used are: 0, 0.025, 0.05, 0.1, 0.25, 0.5 and
1 µM with a constant DNA concentration of 60 nM.    
 
4.4. Analytical Gelfiltration of Complexes of mAIM2 and DNA Ligands Suited for 
Crystallization 
Prior to setting up crystallization screens of AIM2-DNA complexes, potential ligands 
were analyzed for quantitative binding to mAIM2 by analytical gelfiltration (Fig. 28). 
Amongst the four DNA samples tested an 8 bp dsDNA was the only one failing to form a 
stable, detectable complex with the protein (“full length” mAIM2). This might either be due 
to AIM2 requiring more than 8 bp in order to bind efficiently or more likely to instability of 
this short DNA fragment at room temperature. On the other hand three DNA hairpins, with 
varying stem length (11, 18 and 25 hp; Table 7) and harboring a tetraloop, that were derived 
from the successfully crystallized domain E of Thermus flavors 5S rRNA (PDB: 361D9) 
appear to be quantitatively bound. Formation of the protein DNA complex was very efficient, 
resulting in an obvious additional, early eluting peak in gelfiltration, while the initial peak 
corresponding to the DNA by itself was entirely lost. 
Stoichiometries calculated from these elution profiles suggest a single binding side for 
mAIM2 on either the 11 or 18bp hairpin, while more molecules (calculated: 3.5) appear to 
bind to the 25 bp hairpin (Fig. 28). This is in agreement with previously shown EMSAs. 
Interestingly, mAIM2 exhibits a higher molecular weight in analytical gelfiltration than 
in SDS-PAGE.  
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Figure 28  Chromatograms of analytical gelfiltration runs of mAIM2 alone and in 
complex with different RNAs (8 bp dsRNA, 11+4 hp, 18+4 hp, and 25+4 hp) and calculations 
for binding stoichiometries derived from them. Molecular weights were calculated according 
to a run of a molecular weight standard (theoretical MWs: mAIM2 ~ 40.2 kDa, 11 hp ~ 
8 kDa, 18 hp ~ 12.3 kDa, 25hp ~ 16.6 kDa, 8 bp ~ 4.8kDa). 
 
4.5. Crystallization of AIM2 – dsDNA Complexes  
For crystallization and binding assays the longest stable mAIM2 fragment (~37 kDa), 
obtained during purification without any tag was used, initially. For co-crystallization DNA 
hairpins of different lengths (11 bp+4 nt, 18 bp+4 nt and 25bp+4 nt) that had been shown to 
bind to AIM2 and an 8 bp dsDNA, that failed to form a detectable complex with AIM2 in 
gelfiltration, were utilized (Table 7). Protein was used with a concentration of ~10 mg/ml and 
DNA was initially added in stoichiometric amounts.  
Crystals containing the long mAIM2 construct were predominantly obtained in presence 
of the 11 or 18 hp (some for 25 hp and none for the 8 bp dsDNA), in the PEG-based Jena 
Classics HTS I screen as well as the Qiagen Nucleix Suite (Table 10). Setups with solely 
protein or DNA in the same conditions resulted in clear drops or precipitate, respectively, 
suggesting that the crystals contained a complex of both.   
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Table 10 Examples for crystallization hits in initial screens for the complex of either full 
length mAIM2 or HIN domain constructs containing residues 146-354 with an 11 or 18 bp 
hairpin DNA. 
 
Unfortunately, refined crystals for full length mAIM2 – DNA complexes from hanging 
or sitting drop grew either to the plate or in the PEG skin of the drop. These crystals were 
very fragile and were not able to be loop mounted successfully (Fig. 29).  
Edman sequencing results for degradation products of the purified full length mAIM2 
had suggested that the protein construct used for crystallization might contain the C-terminal 
HIN domain and a part of the unstructured region connecting it to the Pyrin domain. 
Therefore, for further crystallization attempts only the HIN domain constructs comprising 
residues 146-354, 94-354 and 137-354 that were not as prone to further degradation were 
used.  
For co-crystallization with the HIN domain constructs only the 11 and 18 bp hairpins 
were used and different protein to DNA ratios were tested (1:1, 1:2, 1:3 and 1:4). Also co-
purification of the protein-DNA complex by gelfiltration has been applied prior to 
crystallization setups. Complexes containing an 11 bp hairpin as DNA ligand yielded the most 
hits in initial crystallization screens. 
 While again many of the conditions favoring crystal growth contained high PEG4000 
conditions, some additional MPD conditions were found in the Jena Classics HTS II screen as 
mAIM2        
Jena Cl I Precipitant I [%] w/v Precipitant II [mM] Precipitant III [mM] Buffer [mM] pH 
C 11 PEG 4000 30 CaCl2 200   HEPES Na Salt 100 7.5 
C 12 PEG 4000 30 Na Acetate 200   TRIS-HCl 100 8.5 
E 9 PEG 4000 32   LiCl 800 TRIS-HCl 100 8.5 
F 7 PEG 6000 28   LiCl 500 TRIS-HCl 100 8.5 
F 8 PEG 6000 30 Na Acetate 100 LiCl 1000    
Nucleix Precipitant I [%] w/v Precipitant II [mM] Precipitant III [mM] Buffer [mM] pH 
H12   MgCl2 10 Spermine 50 Na Cacodylate 50 6.5 
mAIM2 HIN domain (146-354)      
Jena Cl I Precipitant I [%] w/v Precipitant II [mM] Precipitant III [mM] Buffer [mM] pH 
C 7 PEG 4000 25 MgCl2 200   MES Na Salt 100 6.5 
C 8 PEG 4000 25 CaCl2 200   TRIS-HCl 100 8.5 
 C 11 PEG 4000 30 CaCl2 200   HEPES Na Salt 100 7.5 
E 9 PEG 4000 32 LiCl 800   TRIS-HCl 100 8.5 
Jena Cl II Precipitant I [%] w/v Precipitant II [%] w/v Precipitant III [mM] Buffer [mM] pH 
D 4 MPD 50 NaCl 50 iso-Propanol 20 Na Acetate 50  
D 7 MPD 60 CaCl2 10   Na Acetate 100 4.6 
D 8 MPD 70     MES Na Salt 100 6.5 
D 9 MPD 70     TRIS- HCl 100 8.5 
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well as the Qiagen MPD suite (Table 10). However, even though a slight improvement in 
crystal growth was observed when the reservoir size was increased, crystals did not grow to 
reasonable sizes in refinement setups. In addition, heavy precipitation occurred immediately 
after the drop setup, making seeding methods difficult.  
None of the various hit conditions from crystallization screens was able to be refined to 
produce crystals of sufficient quality to be measured. Additionally, setups at different 
temperatures, varying protein concentrations, increasing reservoir volumes, supply of 
additives, addition of TCEP, use of Selenomethionine protein (full length construct), seeding 
and changes in constructs were tested but did not result in improved crystals.  
Figure 29 Crystals of mAIM2 in complex with an 11 bp+4 nt DNA hairpin in refinements 
from Jena Classics I screen, condition F7 or E9, containing 30 % PEG 6000/0.5 M LiCl/0.1 M 
TRIS pH 8.5 or 30 % PEG 4000/0.8 M LiCl/0.1 M TRIS pH 8.5, respectively.  
 
4.6. AIM2 and ASC Interaction 
ASC and its Pyrin domain have been reported to be prone to aggregation when purified 
due to their bipolar character. This was also observed with various ASC-constructs and tags. 
An N-terminal GST-fusion construct of mouse ASC could be purified successfully. Since full 
length ASC protein contains a flexible region between its PYD and CARD, the main focus 
was on purifying PYD-only constructs of mASC and hsASC, as they were anticipated to be 
best suited for structural studies of a ternary DNA-AIM2-ASC(PYD) complex.  
The GST-tagged PYD constructs were equally soluble and removal of the GST-tag by 
PreScission protease digest of the mouse construct in a small scale yielded protein in the 
soluble fraction (Fig. 30), independent of the presence of AIM2. Unfortunately, in larger 
scales, PYD was aggregating after PreScission treatment in either dialysis, batch or on a 
GSH-Sepharose column. 
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Figure 30 Soluble fractions of PreScission treated samples of GST-mASC(PYD) in small 
scale in presence and absence of AIM2. 
 
Due to the difficulties in purifying ASC’s PYD and the degradation of AIM2 in its PYD 
region, that is required for homotypic PYD interactions, testing of complex formation of the 
two proteins and the DNA dependence of this event proved challenging. 
Pulldown experiments were carried out with GST-tagged h/mASC full length or PYD 
constructs and h/mAIM2 constructs containing a His-tag (Fig. 31). The two proteins were 
either co-expressed (from different, but compatible vectors), co-purified (mixing of pellets 
prior to cell lysis) or purified separately. In the latter case, AIM2-6xHis was first purified on a 
Ni-NTA column and the elution fraction was added to GSH-Sepharose resin already pre-
loaded with GST-ASC.  
Pulldown samples were first analyzed by SDS PAGE, which however only gave a vague 
indication of the interaction of recombinant AIM2 with ASC or ASC-PYD. While the GST-
tagged ASC constructs were easily distinguishable (compare Fig. 31, Coomassie stained gel 
lane G and P), AIM2 appeared degraded (Fig. 31 Coomassie stained gel lane H). Furthermore, 
an impurity with an approximate apparent molecular weight in the range of full length AIM2 
made its detection ambiguous.  
Tag-specific immunoblotting of the samples verified a binding of mAIM2 to mASC-
PYD(1-93) (Fig. 31). The interaction was detected for the pulldown of purified mAIM2-6xHis 
by immobilized GST-mASC-PYD(1-93), as well as in case of co-purification and co-
expression of the two constructs by GSH-affinity chromatography. Human constructs and full 
length ASC samples were not immunoblotted but judging from SDS-PAGE analysis (not 
shown) an interaction appears equally likely. 
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Figure 31 Pulldown interaction assay of mAIM2 (C-terminal 6xHis-tag) and mASC-PYD 
(1-93; N-terminal GST-tag). GST-mASC-PYD was immobilized on GSH-Sepharose. Samples 
of protein loaded GSH- or Ni-NTA beads in SDS PAGE or Western blot detected by either a 
GST- or His-tag specific antibody are shown. (M: molecular weight standard; G: GST-
mASC-PYD; H: mAIM2-6xHis; P: pulldown, Ni-NTA eluted mAIM2-6xHis bound to 
immobilized GST-mASC-PYD; O: overlaid pulldown lanes, red - anti-His, blue - anti-GST) 
 
The smaller, faster migrating mAIM2 degradation products are lost in the pulldown 
sample (compare Fig. 31 anti-His H and P) compared to the Ni-NTA elution sample of 
mAIM2. Considering that the detected His-tag is C-terminal and the earlier shown N-terminal 
degradation of AIM2 this proves that the N-terminal AIM2-PYD is required to facilitate 
ASC-PYD interaction. However, a significant amount of mAIM2 species lagging parts of the 
N-terminal PYD can still be pulled down by ASC-PYD, which implies the presence of a 
minimum required binding site in the more C-terminal part of AIM2-PYD.  
A high absorbance at 260 nm in an UV/visible spectrum of mAIM2, used in the pulldown 
assay, indicates that cellular DNA remains bound to its HIN domain during the purification 
steps. DNA might aid AIM2/ASC complex formation and its dependence needs to be further 
assessed.This assay also shows that a fraction of undegraded AIM2 can be obtained if only an 
affinity purification step is applied. The presence of ASC-PYD might even stabilize AIM2 
and prevent its entire degradation. The apparent molecular weight of the presumed full length 
mAIM2 appears higher than the theoretical one.  
The verification of the complex formation between AIM2 and ASC is a prerequisite for 
the identification of minimal interacting constructs as crystallizable inflammasome 
subcomplexes. Moreover, this finding makes fusion proteins of AIM2 and ASC or ASC-PYD 
valid crystallization targets.  
To further improve the stability of AIM2/ASC complexes, future expression of the single 
components or fusion proteins in insect cells might be of advantage. 
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A list of cloned constructs and fusion proteins is shown in Table 11. Most of the already 
tested fusion-constructs could be expressed and were initially soluble; but unfortunately they 
were lost during purification due to aggregation. Optimization of purification conditions could 
help to improve this. 
More of the already cloned fusion-constructs (Table 11) need to be tested for soluble 
expression and stability during purification. Expression in a baculovirus / insect cell system 
was not attempted for the single or fusion constructs. AIM2 expressed in insect cells however, 
could be more stable and the introduction of post-translational modifications or 
phosphorylations, even though not mammalian like, could improve complex formation 
between AIM2 and ASC. 
 
Table 11 List of hitherto cloned constructs of AIM2 and ASC from mouse and human 
and fusion variants with respective vectors. A “+” indicates the existence of the construct, 
with green background indicating good solubility, yellow for limited solubility and red for 
insoluble expression right away. White “+” fields depict existing clones that yet need to be 
tested for expression and solubility. 
  
  
pFBDM 
(6His-
PreSc) 
pET21a 
(STOP) 
pET21a 
(C-6His) 
pET28 
(N-6His) 
pET28 
(N-6His+ 
SUMO1) 
pGEX6P2 
( N-GST) 
pGEX4T-1 
(N-GST) 
AIM2 
mm + + + + - - - 
hs + + + + + + - 
AIM2 (HIN-200) 
mm(94-354) - + - - - - - 
mm(137-354) - + - - - - - 
mm(146-354) - + - + - - - 
hs(140-343) - + - + - - - 
ASC 
mm - - - - + + - 
hs - - - + - - - 
ASC (PYRIN) 
mm(1-93) - + - + + + - 
hs(1-92) - + - + - + - 
ASC(PYRIN)_20 
(PreSc)_AIM2 
mm + + - + - - - 
hs - - - - - + - 
ASC(PYRIN)_11 
(PreSc)_AIM2 
mm + - - + + + + 
hs - - - - - + - 
ASC_20(PreSc)_
AIM2 
mm - - - + - - + 
hs - - - - - - + 
ASC_11(PreSc)_
AIM2 
mm - - - - - + + 
hs - - - - - - - 
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5. Discussion 
Pattern recognition receptors of the innate immune system that are responsive to nucleic 
acids must be especially sensitive and specific when it comes to recognition of their particular 
pattern. They have to be able to strictly discriminate between intrinsic and pathogenic nucleic 
acids to prevent false signaling and auto-immune reactions. Their cytosolic localization 
represents a prerequisite for concise pattern detection. Furthermore, there is a need for a range 
of different receptors that are highly specialized for sensing certain subtle modifications or 
patterns characteristic of pathogenic nucleic acids only. 
RIG-I like receptors represent a group of cytosolic helicases that facilitate the detection 
of viral or virus derived RNA motives and trigger pro-inflammatory signaling in response. 
For example, RIG-I has been shown to discriminate RNAs by the presence of a
5’-triphosphate, a common pattern in replicating viruses. Since intrinsic RNAs are usually 
processed or capped this pattern is solely pathogen associated.  
It could be confirmed that the C-terminal domain is indeed regulatory rather than 
repressing and confers pattern recognition in RLRs. This is corroborated by locating and 
characterizing the RNA interaction sites in RDs and by emphasizing differences in molecular 
details that contribute to differing pattern specificity amongst the group. In particular, the 
crystal structure of the RD of LGP2 was solved and extensive analysis of its RNA-binding 
behavior was conducted. Thus, a better understanding of the regulatory mechanism that LGP2 
exhibits on RLR signaling was gained.  
With AIM2, an inflammasome forming PRR directed against DNA was analyzed. In 
addition, its interaction with DNA and the inflammasomal adaptor ASC was studied. 
Constructs and DNA ligands could be identified that appear suitable for crystallographic 
analysis. Thus, strong progress towards the determination of molecular structures of AIM2 
inflammasome subcomplexes has been made. 
 
5.1. RLR Regulatory Domains Have a Common RNA Binding Site 
A comparison of the solved crystal structure of LGP2 RD with structures of the RDs of 
RIG-I (PDB: 2QFD) and MDA5 (PDB: 3GA3) reveals the extremely high structural 
conservation of this domain amongst the group of RLRs (Fig. 32 A). 
The crystal structure of LGP2 RD combined with functional analysis exhibits a highly 
positively charged cleft on the concave surface that confers RNA ligand binding, similar to 
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RIG-I RD. A single conserved Lysine residue in the center of this positively charged patch 
has been proven to be indispensible for RNA interaction of LGP2 RD. This K634 corresponds 
to K888 in RIG-I that has been established as equally crucial.   
The MDA5 RD structure was initially modeled (Pippig et al. 2009) but more recently an 
experimental structure (PDB: 3GA3) (Li et al. 2009a) was released. Both MDA5 RD 
structure and model reveal a positively charged concave surface similar to the RD of RIG-I 
and LGP2. Thus, the area can be highlighted as an important RNA recognition site in RLR 
RDs. In addition, the conserved lysine residue, K984MDA5, found to be essential for RNA 
binding by RIG-I and LGP2 RD, is situated at the same position as K888RIG-I and K634LGP2 (Fig. 
32 B). 
The results allow to postulate a common core RNA binding site for the region around 
this conserved lysine and 310 helix η4 in the positively charged groove of RLR RDs. 
 
Figure 32 (A) Superposition of the crystal structures of RLR RDs with the proposed RNA 
ligand specificity and core RNA binding site highlighted. (LGP2 RD: green sheets, black 
helices, grey loops; RIG-I RD: pale orange; MDA5 RD: pale yellow). (B) Comparison of the 
surface charge potential of the concave side of RLR RDs with important residues and the 
RNA interaction sites highlighted (PDB: 2W4R, 3GA3, 2QFD). 
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Recent structures of RIG-I (PDB: 3LRR, 3NCU) and LGP2 RD (3EQT) in complex with 
blunt end dsRNA and a 5’-triphosphate in the case of RIG-I correlate with this finding. The 
conserved lysine forms hydrogen bond contacts with the non-bridging phosphate oxygens of 
the α phosphate in RIG-I RD, while the corresponding lysine in LGP2 appears to be in 
hydrogen bonding distance for either the analog terminal backbone phosphate or the 
subsequent one (see chapter 5.1.2., Fig. 33 B, C). 
 
5.1.1. RLR RNA Binding Specificities are Determined by a Variable Loop Region in the RD 
Despite the common RNA binding site, LGP2 has been shown to exhibit different ligand 
specificity to RIG-I with the regulatory domain conferring discrimination between certain 
RNA species. While the RIG-I RD ligand was initially thought to be nonspecific 
5’-triphosphate containing RNA, it has recently been more accurately determined to be blunt 
end dsRNA containing a 5’-triphosphate (Schlee et al. 2009; Schmidt et al. 2009). In contrast, 
LGP2 RD also preferably binds blunt end dsRNA, however this is entirely independent of the 
presence of a 5’-triphosphate moiety.  
Mutational studies of LGP2 RD suggest that an area centered on β-sheet 6 that is directly 
adjacent to a flexible loop and harbors various unconserved but functionally important 
residues, including W604 and P606 confers selectivity in binding different RNAs. Also MDA5 
differs from RIG-I and LGP2 in this region of the RD. It for example possesses an isoleucine 
(I956MDA5) in the place of P606LGP2 or K858RIG-I, thereby the presence of the proposed ligand 
specificity site is underpinned. Nevertheless, for MDA5, the nature of the PAMP likely sensed 
by its RD remains to be further investigated. Its ligand specificity might correlate more with 
LGP2, given the absence of an additional positively charged triphosphate binding pocket 
(K849/K851) that is only present in RIG-I but not the other RDs.   
 
5.1.2. LGP2 RD Binds to dsRNA Ends 
From EMSAs and fluorescence anisotropy titration experiments using wildtype LGP2 
RD and point mutated variants a specific binding of LGP2 RD to blunt double strand RNA 
ends can be concluded. This is based on the appearance of two differently sized distinct RNA 
shifting complexes in EMSAs, while a dimer formation of LGP2 RD in presence of RNA was 
never observed. Also, in fluorescence anisotropy competition assays an RNA double strand 
with two blunt ends was bound preferentially over a hairpin RNA of similar stem length. 
Furthermore, LGP2 RD’s binding to RNA exhibits no obvious sequence specificity, making 
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the presence of two such specific binding sites along the RNA double strand very unlikely. If 
more RD molecules are able to non-specifically bind along the RNA rather than at the ends, a 
less distinct complex formation would be expected, as was found for RDs with point 
mutations in the proposed specificity site. 
This proposal is supported by a recently solved structure of LGP2 RD in complex with a 
hexameric dsRNA (3EQT) (Li et al. 2009b). Superposition of the apo-protein with the RNA 
bound version does not show any significant conformational changes. Both molecules are 
very similar as can be seen by the virtually identical Zn2+-coordination site (Fig. 33 A). Closer 
examination of the RNA-interacting residues, that we identified by mutational studies, only 
exhibits minor changes. While H576 has the entirely same position in the superposed 
molecules and K634 only slightly differs in its sidechain orientation, W604 is more exposed in 
the complex structure. This allows for RNA interaction as opposed to a buried orientation in 
apo-LGP2 RD. All three residues are within hydrogen bonding distance to either the 
phosphate backbone (K634) or sugar oxygens (H576, W604) of the RNA ligand (Fig. 33 B). 
 
Figure 33 (A) Superposition of apo LGP2 RD (2W4R; green, black, grey) with the RNA 
bound molecule (3EQT; pale yellow). Electrostatic potential shown for apo LGP2 RD ranges 
from -5 kT (red) 5 kT (blue). (B) Comparison of single residues of LGP2 RD in RNA bound 
and apo state with likely hydrogen bonds between protein side chains and RNA. (C) Possible 
lid-like interaction of the unstructured loop region between β5 and β6 with bound RNA. 
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Another conclusion from the initial LGP2 RD structure was that the region between
β-sheets 5 and 6 forms a loop that is not defined in the electron density due to its flexibility. 
This loop appears to shield the specificity side around W604 from the surface by slightly 
burying it. Additionally, in the complex structure the loop appears to form a lid on top of the 
dsRNA. Flexibility in this region therefore makes sense, to allow RNA to enter the binding 
site and then be retained by “closing the lid”. Further residues in this region such as F601 or 
K599 seem capable of interaction with the RNA by either hydrogen bonds or base stacking 
(Fig. 33 C). Interestingly, the flexible loop region between β-sheets 5 and 6, located in close 
proximity to the ligand specificity site around P606LGP2/K858RIG-I, appears to be ordered in a 
RIG-I RD-RNA complex structures (PDB: 3NCU), extending β-sheet 5 (Fig. 34 A, B) (Wang 
et al. 2010). This also suggests that this region is disordered and flexible in an unbound state 
and only becomes structured upon ligand interaction of RDs. The extended β-sheet 5 seems to 
stack on the blunt RNA end in the described lid-like manner. 
 
Figure 34 Comparison of the RIG-I RD apo structure (2QFD) (A) with the synthetic 
5’-triphosphate bound state (3NCU) (B). β-sheets 5 and 6 and the proposed lid with β5 closed 
on top of the dsRNA ligand are highlighted. 
 
The structure of this RIG-I RD complex with a synthetic 5’-triphosphate blunt end 
dsRNA (3NCU) has been solved only recently and is also in perfect agreement with the core 
RNA binding and specificity site model proposed here (Wang et al. 2010). Generally, the 
ability of either LGP2 or RIG-I RDs to bind to the ends of dsRNA would appear to be 
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advantageous for complex crystallization by allowing a good crystal packing arrangement 
with two molecules bound to each end of a fairly short blunt end dsRNA (6 or 12 bp).     
Dimer formation of LGP2 RD upon dsRNA binding was never observed. This is also 
confirmed by the crystal structure (PDB: 3EQT) of the complex (Li et al. 2009b). Full length 
LGP2 has however been shown to form dimers, suggesting an activation mechanism related 
to that of RIG-I (Cui et al. 2008; Murali et al. 2008). 
 
5.2. LGP2 as a Regulator of RIG-I and MDA5 Signaling 
The function and mechanism of LGP2 as a regulator in antiviral innate immune response 
is puzzling. Previous analysis of LGP2 deficient mice had uncovered a surprising dichotomy 
of LGP2 function with respect to regulation of RIG-I and MDA5 activity. Whereas LGP2-
deficient mice showed reduced susceptibility to viruses recognized by RIG-I, these mice show 
enhanced susceptibility to challenge with MDA5-specific viruses like EMCV (Venkataraman 
et al. 2007). 
To test the LGP2 RD characterizing findings that were gained by in vitro analyses and to 
draw conclusions that could be also applied to full length LGP2, interferon-β reporter assays 
in HEK293 cells were conducted in collaboration (Pippig et al. 2009). Thus, the regulatory 
effect of LGP2 and the respective contribution of its domains on MDA5 and RIG-I signaling 
could be assessed (Fig. 35).  
To clarify the mechanisms by which LGP2 differentially regulates RIG-I and MDA5 and 
the role of its RD in these processes, increasing amounts of LGP2 were co-expressed with 
RIG-I or MDA5 in HEK293 cells. Activation of a luciferase-based interferon-β reporter assay 
system after stimulation with the appropriate RNA ligand was monitored.  
As demonstrated before, when co-expressing LGP2 together with RIG-I, loss of 
interferon-promoter activation was observed proportional to the level of LGP2 over-
expression (Rothenfusser et al. 2005; Venkataraman et al. 2007). Contrary, when MDA5 was 
co-expressed with different amounts of LGP2 in the presence of the dsRNA analog poly(I:C) 
optimal activation, rather than repression was observed at LGP2 expression levels similar to 
those of MDA5. This was consistent with the weak virus induced MDA5 response seen in 
LGP2 deficient mice (Venkataraman et al. 2007).  
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Figure 35 (A) Interferon-β reporter assay of Hek293 cells, transfected with plasmids 
encoding RIG-I-HA (10 ng plasmid, HA: Hemagglutinin-tag) and different amounts of LGP2-
HA (2, 5, 10 and 50 ng plasmid) and stimulated with 5’ppp RNA. Alternatively, cells were 
transfected with RIG-I-HA and different amounts of wildtype (wt), N-terminal (NT, aa 1-468) 
or C-terminal (RD, aa 476-678) constructs of LGP2-HA. (B) Cells were transfected with 
plasmids encoding MDA5-HA (1 ng plasmid) and different amounts of LGP2-HA (0.05, 0.1, 
1, 5, 50 and 100 ng plasmid) and stimulated with poly(I:C). Alternatively, cells were 
transfected with MDA5-HA and different amounts of wt, NT or RD constructs of LGP2-HA. 
 
Relative contributions of the two LGP2 functional domains (DExH helicase domain - NT 
and regulatory domain - RD) towards RIG-I repression and MDA5 activation were examined. 
This was conducted in the presence of different levels of either full-length LGP2 or one of the 
two functional domains. As has been observed before, LGP2 RD alone is also able to mediate 
RIG-I repression albeit more weakly than the full length protein (Saito et al. 2007). 
Consistently, an additive contribution of the helicase domain to LGP2-mediated repression of 
RIG-I is detected (Fig. 35 A). 
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On the other hand, while full length LGP2-mediated MDA5 activation happened as 
expected, no stimulation was observed in presence of different amounts of either LGP2 
helicase domain or RD only (Fig. 35 B). Hence a fully functional LGP2 is required to mediate 
a synergistic effect on MDA5, while the inhibitory effect on RIG-I signaling appears additive 
concerning domain contribution.  
Explanations for this controversial role of LGP2 remain speculative. More recently LGP2 
has again been demonstrated to exhibit a positive effect on MDA5 but also on RIG-I signaling 
(Satoh et al. 2010). Rather than direct interaction a function for LGP2 upstream of RIG-I and 
MDA5 signaling cascades has thereby been proposed. It can be speculated that LGP2 can 
bind to RNA in the cytosol that is highly structured or coated by proteins with high affinity. 
By means of LGP2’s helicase and ATPase activity the RNA ligand could then be cleared to 
allow for accessibility by the other two RLRs.  
Consequently, LGP2 can be assumed to act in mechanistically differing ways and various 
regulatory scenarios could be possible (Fig. 36). 
 
5.3. Possible Mechanisms of LGP2 Interference with MDA5 and RIG-I Signaling 
Inhibitory effects of LGP2 have so far only been indicated towards RIG-I signaling. 
LGP2 RD has been suggested to interact in trans with the RIG-I CARDs. Thereby, RIG-I is 
kept in an inactive conformation, by preventing CARD exposure for downstream signaling 
(Fig. 36 A) (Saito et al. 2007).  
LGP2 has also been demonstrated to interact with the RIG-I downstream signaling 
mediator IPS-1. It was shown to compete for IKKε binding in a section spanning IPS-1’s 
transmembrane domain and part of its unstructured region. LGP2’s binding to IPS-1 is 
supposedly virus and RNA-independent. Also, IPS-1 RIG-I interaction has been shown to be 
unaffected. So, this represents a passive mode of inhibition of RIG-I signaling by LGP2 (Fig. 
36 B) (Komuro et al. 2006; Vitour et al. 2007).  
A third explanation for LGP2’s repressive effect on RIG-I signaling is more in coherence 
with the finding that both the helicase domain and RD of LGP2 can be inhibitory with effects 
being additive. In this case the high affinity of LGP2 and its domains to potential RIG-I RNA-
ligands would account for its functioning as a sink for dsRNA in the cell. Thereby RNA is 
inaccessible for recognition by RIG-I. This latter scenario would presumably be dosage 
dependent, LGP2 might confer regulation in a negative feedback loop when upregulated in 
response to viral stimuli.  
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Figure 36 Possible mechanisms of RIG-I and MDA5 regulation by LGP2. Red and green 
frames represent inhibitory or activating effects, respectively. (A) RIG-I inhibition by trans-
interaction of LGP2 RD with its CARDs. (B) Passive inhibition by LGP2 competition with 
IKKε for IPS-1 binding. (C) Possibly active heterodimeric RLR-RNA complexes and (D) 
LGP2’s mode of dsRNA interaction and possible processing by removal of bound or stalled 
protein or secondary structure. Domains are depicted in shades of green (RDs), red (CARDs – 
“C”) and blue (helicase domain – “DECH”).   
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A further explanation is that LGP2 could be an activator of RIG-I and MDA5 signaling 
by forming heterodimers upon RNA exposure that are capable of signal transduction. This 
especially applies to MDA5, whose exact RNA PAMP is still subject to controversial 
discussion, and where heterodimer formation might be an explanation for missing knowledge 
about an MDA5-only ligand (Fig. 36 C). Even though, heterotypic interactions between the 
RLRs have been shown by whole cell extract pulldowns of virus infected cells, so far no 
evidence for such complexes exist from in vitro experiments (Komuro et al. 2006).    
Finally, recent studies indicate an activating role of LGP2 operating upstream of RIG-I 
and MDA5 (Satoh et al. 2010). LGP2 might interact with RNA similarly to RIG-I by first 
docking to dsRNA with its RD and subsequent dimerization of the helicase domain. It is 
possibly more versatile in binding to various RNA conformations and could therefore make 
initially unrecognized RNA accessible to RIG-I and MDA5. By helicase movement along the 
dsRNA strands LGP2 could remove other RNA bound or stalled proteins or eliminate 
secondary structure. Thus translocation of either MDA5 or RIG-I would be enabled 
subsequently (Fig. 36 D). If the helicase activity of RIG-I and MDA5 was actually required 
for their signaling, LGP2 could also function in releasing stalled RLRs, thus ensuring their 
availability for further signal transduction.  
LGP2 could also represent a means of bringing sensor ( RIG-I or MDA5) and signaling 
or mediator molecules (like IPS-1) in close proximity to stimulate downstream signaling. If 
this was the case, the observed LGP2 interaction with IPS-1 would appear in an activating 
context. 
In general, LGP2’s regulatory effect on RLR signaling is still controversial. It is likely to 
be dosage dependent and highly regulated itself. Hence, a stimulating effect on RIG-I 
signaling as well as its inhibition by LGP2 are not mutually exclusive.  
At low or normal expression levels LGP2 could activate RIG-I and MDA5 signaling by 
different possible mechanisms (Fig. 36 C, D).  
During progress of the inflammation and to prevent exaggerated immune reactions or 
false-positive signaling by RIG-I, LGP2 might be upregulated. High levels of LGP2 would 
then increase the competition for RNA in the cytosol. LGP2 can bind to RNA with high 
affinity and less specificity than RIG-I. This prevents RIG-I’s binding to RNA and suppresses 
subsequent signaling events (Fig. 36 A). This interpretation is also in coherence with the 
finding that LGP2 RD by itself is able to abrogate RIG-I activity in vivo. LGP2 RD could 
bind to 5’-triphosphate containing dsRNA ends and block them, thus impeding RIG-I loading 
onto the RNA. 
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As yet unidentified proteins might further be involved in this tightly regulated network 
that could aid LGP2’s modulating effect. 
It seems that the variability of results, gained by in vivo assays which demonstrate 
LGP2’s role as regulator of RIG-I and MDA5 signaling, might partially originate from the use 
of varying stimuli. It can be assumed that synthetic RNA ligands and especially Poly(I:C) do 
not cause an entirely physiological relevant response. Moreover, RIG-I and MDA5 exhibit 
susceptibility towards different viruses. Thus, a careful selection of the viral stimulus as well 
as a greater knowledge of structural characteristics of the RNA it harbors, are indispensible to 
allow for proper conclusions from the assay results.    
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5.4. The AIM2 Inflammasome – Preliminary Functional Insights 
RLRs are capable of directly triggering an immune response upon sensing pathogenic 
RNA in the cytosol. The AIM2 inflammasome and others however, represent a second stage 
of inflammatory response by processing inflammatory cytokines like pro-IL1β that result 
from the primary reaction. 
The AIM2 inflammasome is unique compared to other inflammasomes and yet more 
unknown inflammasomes might exist in this tightly regulated signaling network. Even RIG-I 
that has recently been shown to interact with the common inflammasome adaptor ASC, as 
does AIM2, might be a candidate for a new RNA responsive inflammasome-like platform.  
Recombinantly expressed AIM2 could be shown to bind dsDNA and certain 
crystallization suited DNA-ligands have been identified.  
It is proposed that AIM2 forms higher oligomeric complexes upon binding to DNA, 
whereby oligomerization is mediated by the conserved MFHATVAT motif located in the 
C-terminal DNA binding HIN domain. Yet, in binding studies a maximum of only two 
binding sites are apparent, judging from two distinctly shifted bands in EMSAs. However the 
longest used oligonucleotide had 35 bp only and it has been shown that interaction is length 
dependent and at least around 40 bp are required to trigger AIM2 inflammasome formation in 
vivo (Fernandes-Alnemri et al. 2009; Roberts et al. 2009). This indicates that AIM2 
oligomerization is possibly facilitated by binding of a certain number of AIM2 molecules next 
to each other on a dsDNA strand.  
Binding per se seems to be rather strong even with shorter dsDNA. Also protein-DNA 
complexes are stable enough to withstand purification in size exclusion chromatography. 
Aggregation of the human AIM2-HIN domain constructs when exposed to dsDNA might also 
indicate the formation of larger complexes. 
An interaction between recombinant AIM2 and ASC or ASC-PYD in presence of DNA 
could be demonstrated. This represents a first step towards identifying crystallizable bi- or 
tripartite inflammasomal subcomplexes. Future improvement of the stability of the individual 
AIM2 inflammasome components or determination of a self-stabilizing complex will however 
be required for this purpose. While AIM2 was rarely prone to aggregation, it undergoes rapid 
N-terminal (PYD domain) degradation. ASC and its PYD-only constructs proved challenging 
to handle, because of the strong bipolar character that would often lead to aggregation of the 
purified protein after GST-tag cleavage, especially in physiological pH ranges. 
For the NLRP1 inflammasome a penta- or heptameric ring-like structure has been 
proposed (Faustin et al. 2007) and it is also possible that AIM2 would form ordered 
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multiprotein platforms upon recognition of cytosolic dsDNA. If the AIM2 inflammasome was 
also appearing in heptameric clusters, either a ring-like shape or a more linear conformation 
could be possible (Fig. 37), however no experimental evidence exists for this. The AIM2 
inflammasome could however also be more of an unordered cluster induced by multiple 
neighboring AIM2 binding sites on dsDNA. In the future, it will be important to determine 
the exact inflammasome stoichiometry. It is also of interest to see whether in such complexes 
each AIM2 molecule would exhibit DNA contacts or whether binding of a sub-complex is 
enough to trigger further building block recruitment. In this model oligomerization could be 
mediated by either AIM2’s dimerization motive or by ASC – ASC interactions.   
 
 
Figure 37 Theoretical schemes for complex formation of the AIM2 inflammasome. 
Stoichiometries are indicative only. AIM2 binds dsDNA with its HIN domain and attaches 
ASC via homotypic PYD interaction. Subsequently pro-caspase 1 is recruited by CARD 
interaction to form a catalytically active caspase complex after auto-cleavage.   
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5.4.1. Crystallization of AIM2 – DNA Complexes 
Even though crystals that possibly contain the AIM2-DNA complex (or HIN-DNA) 
could be already grown, improvement is required to gain good quality crystals for final 
structure determination. Major problems were a generally high number of crystallization 
nuclei and the crystals growing bound to the plate. Crystallization in an agarose gel matrix 
might help to circumvent this. The so far used DNA-hairpins may also not be ideal for 
optimal crystal packing and more DNA species, namely blunt end dsDNA of different 
lengths, need to be tested for crystallization. Once a stable complex of AIM2 and ASC/ASC-
PYD is established in large scale this should be crystallized in presence of DNA as well. 
Despite the proposed higher oligomeric molecular structure of the inflammasome and judging 
from here shown results, it appears likely that certain AIM2 inflammasome subcomplexes 
could crystallize.    
 
5.5. Comparison of RLRs and AIM2 
RLR and AIM2 have several things in common. They are cytosolic receptors directed 
against pathogenic nucleic acids that enter the cell during infection. Upon recognition of their 
respective PAMP, they trigger pro-inflammatory or antiviral responses. So far, RIG-I is the 
best characterized RLR and believed to form dimers after interaction with 5’-triphosphate 
dsRNA, that can also originate from RNA Polymerase III transcribed cytosolic DNA. RIG-I 
signals downstream via its CARD domains. The RIG-I pathway gets thereby localized to the 
mitochondrial membrane, forming a large antiviral signaling focus.  
AIM2 on the other hand forms higher oligomeric assemblies upon interaction with 
dsDNA that is marked as foreign by its occurrence in the cytosol. For ultimate activation, 
AIM2 binds the inflammasomal adaptor ASC that then recruits pro-caspase 1 also via CARD 
domain interaction. While RLRs MDA5 and RIG-I mainly trigger the production of 
interferons and pro-interleukins, the fully functional AIM2 inflammasome processes the 
latter. This again represents a common intersection between the two pathways. 
  Finally, RIG-I has recently been shown to also interact with ASC through CARD 
domain interaction. So, it can be speculated that it is able to form an inflammasome-like 
structure similar to AIM2, but in response to RNA rather than DNA. 
LGP2 is different due to its lacking an active signaling function. While RIG-I and MDA5 
have CARDs and AIM2 has a Pyrin domain for downstream signal transduction, LGP2 is 
restricted to a regulatory role.  
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In the AIM2 inflammasome network mp202, or similarly acting possible splice variants 
of human AIM2, come closest to be comparable with LGP2. They represent an analog way of 
regulation by being able to interact with dsDNA and AIM2, but lacking the adaptor PYD 
required for referring a signal to ASC. 
Generally, it seems to be a common regulatory motive in PRRs of the innate immune 
system to have a highly similar counterpart that is deficient in a domain required for 
downstream interaction. The inhibitory or regulatory effect then lies in the association of this 
limited counterpart with the fully functional PRR. Other examples for this are COPs and 
POPs that either harbor only a Pyrin domain or CARD and are thus capable of interfering 
with ASC signaling.  
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6. Summary 
With LGP2, a member of the RIG-I-like receptor family and AIM2, a recently 
discovered, unusual inflammasome module, two cytosolic pattern recognition receptors of the 
innate immune system could be characterized in the course of this PhD thesis.  
LGP2 has been shown to be a potent and specific receptor of viral, especially duplex 
RNA, despite its lack of CARD domains that are thought to be indispensible for direct signal 
relaying in the RLR pathway. Hence, LGP2 is not directly mediating the expression of pro-
inflammatory cytokines, but it is involved in the regulation of RLR signaling and thus 
cytokine production.  
AIM2 is only partially capable of an upregulation of cytokine expression levels upon 
infection. It is more importantly required for the processing of cytokine precursors originating 
for example from an active RLR pathway. In contrast to the RNA receptor LGP2, AIM2 has 
been shown to specifically bind dsDNA in the cytosol. 
Together, LGP2 and RLRs in general as well as AIM2 represent crucial entities directed 
against diverse pathogens that can infect a cell, by means of detecting their nucleic acid 
constituents. 
It could be demonstrated that the regulatory C-terminal domain in RLRs is indispensible 
for their RNA recognition and interaction. The structure of LGP2 RD could be solved and it 
has been shown to exhibit a strong affinity towards blunt dsRNA. Notably LGP2 RD 
facilitates this contact entirely independent of the presence of phosphates at the 3’- or
5’- RNA-ends. This is in direct contrast to RIG-I that exhibits strongest binding and activation 
in presence of a 5’-triphosphate moiety, a common feature in viral genomes that usually 
remain unprocessed or non-capped. Although the RD of LGP2 exhibits high structural 
similarity to the RD of RIG-I, it exhibits remarkably different RNA binding specificities. 
Thus, the results imply that the regulatory domains of RLR confer their pattern specificity.     
The structure and data suggest that RDs of all three RIG-I like helicases are highly 
conserved RNA binding elements with a common core RNA binding site but specific 
adaptation to their respectively recognized patterns. A shared RNA binding and varying 
specificity sites in RLR RDs were postulated. In particular the properties found specific for 
LGP2 gave rise to possible explanations of the regulatory mechanism it exhibits on RIG-I and 
MDA5 signaling. In case of an inhibitory function of LGP2 on RLR signaling, this might 
occur as a negative feedback to prevent continuous stimulation of pro-inflammatory factors. 
Either the sequestration of RNA by high affinity exhibiting LGP2 or the formation of a 
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hetero-complex of LGP2 with RIG-I or MDA5 that is not capable of signaling are 
possibilities. The latter case has however never been shown and could still be functional in 
signal transduction to IPS-1. For the activating function of LGP2 and aside from the possible 
formation of active hetero-dimers, a role upstream of RIG-I and MDA5 has been suggested. 
LGP2 would thereby act as a rather universal RNA receptor capable of processing and 
clearing viral RNA structures to make them accessible for RIG-I and MDA5. The postulated 
role of LGP2 RD could account for both the inhibitory and activating task and it seems that 
mainly the dose of LGP2 is decisive as for which effect prevails. 
The AIM2 inflammasome project is still emerging. A structure of AIM2 or its complex 
with DNA could not be solved. However, progress has been made towards the identification 
of possible DNA ligands that are favorable to result in diffracting crystals harboring an 
AIM2-DNA complex in the future. This is especially interesting since inflammasome 
formation in vivo has been only reported to occur with dsDNAs containing at least 40 base 
pairs. In vitro, however, strong complex formation is already achieved with 11 bp, which 
should allow for good crystal packing in co-crystallization experiments. Crystals of a complex 
containing the HIN domain of AIM2 or a supposedly N-terminally degraded full version and 
short DNA hairpins were able to be reproducibly grown. 
The identification of recombinant AIM2 and ASC constructs capable to interact with 
each other represents a huge step towards the in vitro reconstitution of the AIM2 
inflammasome or subcomplexes of it. In the future this should provide insight into the 
stoichiometry and complex formation of this pro-inflammatory platform. 
The AIM2 inflammasome, containing AIM2, ASC as well as caspase-1 in unknown 
stoichiometry, tends to form into huge aggregates in cells infected by pathogenic DNA. 
Nevertheless, judging from the obtained results, it appears as a reasonable target for 
crystallization of at least subcomplexes, for example the DNA-AIM2-ASC or DNA-AIM2-
PYD(ASC 1-93) part. 
In conclusion, good progress has been made in testing AIM2’s DNA binding capacity in 
vitro and identifying DNA ligands suited for co-crystallization. Generally, advancement has 
been made into finding constructs that might readily crystallize. Hence, the solution of high-
resolution structures of parts of the AIM2 inflammasome in the near future seems realistic. 
To the RLR field this PhD project is of great importance. It especially helped to extend 
the understanding of LGP2’s role in RLR signaling regulation. Also, insight into the 
mechanism underlying RNA ligand binding and the varying specificity apparent in RLRs has 
been provided.     
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List of commonly used abbreviations. Bases and amino acids (single or three letter code) as 
well as measures and units were abbreviated according to standard nomenclature. 
5'PPP  5' Triphosphate 
  6-FAM  6-Carboxyfluorescein 
 aa  amino acids 
  AF488  AlexaFluor488 
  AIM2  Absent in melanoma 2 
 as  anti sense strand 
  AP-1  Activator protein 1 
  ASC  Apoptosis-associated Speck-like protein containing a CARD 
Bcl-10  B-Cell Lymphoma 1ß  
 BIR  Baculoviral inhibitor of apoptosis proteins repeat 
BSA  Bovine serum albumine 
 CARD  Caspase activation and recruitment domain 
CARDIF  CARD adaptor inducing interferon-β 
C/EBPβ  CCAAT enhancer binding protein β 
 CLR  C-type lectin receptor 
 COP  CARD only protein 
  DAI  DNA-dependent activator of IRF 
DAMP  Danger/damage-associated molecular pattern  
DDX3  DEAD (Asp-Glu-Ala-Asp) box polypeptide 3 
DF  Death-fold   
  dsRNA/DNA  doublestrand RNA/DNA 
 DTT  Dithiothreitol 
  EDTA  Ethylenediaminetetraacetic acid 
EMCV  Encephalomyocarditis virus 
 EMSA  Electrophoretic mobility shif assay 
FADD  Fas-associated via death domain 
FF  Fast flow resin 
  FINDII  F-interacting domain/domain with a function to find 
FL  Full length 
  fwd  forward primer 
  GST  Glutathion-S-Transferase 
 HCV  Hepatits C virus 
  HDV  Human delta virus 
  HEPES  N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
HFIP  Hexafluoroisopropanol 
HIN200  Hematopoietic interferon-inducible nuclear proteins with a 200-amino acid repeat 
HMGB  High mobility group box 
 hp  hairpin 
   HTS  High throughput screen 
 IEC  Ion exchange chromatography 
iE-DAP  γ-D-glutamyl-meso-diaminopimelic acid 
IFN  Interferon  
  IkB  Inhibitor of NF-κB 
  IKKß  I kappa B kinase ß  
  IL  Interleukin 
  IPAF  Interleukin-1β converting enzyme Protease Activating Factor  
IPS-1  Interferon-beta promoter stimulator protein 1 
IRF  Interferon regulatory factor 
 IVT  In vitro transcription 
 LGP2  Laboratory of genetics and physiology 2 
LPS  Lipopolysaccaride 
  LRR  Leucine-rich repeat  
 MaR  Mannose receptor 
  MAVS  Mitochondrial anti-viral signaling protein 
MDA5  Melanoma differentiation-associated gene 5 
MDP  Muramyl dipeptide 
  MES  4-Morpholineethanesulfonic acid 
MINCLE  Macrophage-inducible C-type lectin 
Abbreviations 
 
MPD  Methylpentanediol 
  MR  Molecular replacement 
 MsrB  Methionine sulfoxide reductase 
MSS4  Guanine nucleotide exchange factor MSS4 
MW  Molecular weight 
  NACHT  Domain found in NAIP, CIITA, HET-E and TP1 
NAIP  Neuronal apoptosis inhibitory protein 
NALP  NACHT domain- leucine-rich repeat-, and PYD-containing protein  
NAP1  NF-κB-activating kinase-associated protein 1   
NBD  Nuleotide binding domain 
 NBS  Nucleotide binding site 
 NEMO  NF-kappa-B essential modulator 
NF-κB  nuclear factor "kappa-light-chain-enhancer" of activated B-cells 
NLR  Nod-like receptor  
  NLRB  NOD-like receptor family,BIR domain containing 
NLRC  NOD-like receptor family, CARD domain containing  
NLRP  NOD-like receptor family, pyrin domain containing 
NLS  Nuclear localization sequence 
NOD  Nucleotide binding and oligomerization domain  
nt  nucleotides 
  NTA  Nitrilotriacetic acid  
 OB  Oligonucleotide/-saccharide binding domain 
PAGE  Polyacrylamide electrophoresis 
PAMP  Pathogen-associated molecular pattern  
PEG  Polyethylenglycol 
  pI  Isoelectric point 
  Pol III  RNA Polymerase III 
  POP  PYD only protein 
  pRb  Retinoblastoma protein 
 PRR  Pattern recognition receptor 
 PYCARD  PYD and CARD domain-containing protein 
PYD  Pyrin domain 
  RD  Regulatory (repressor) domain 
rev  reverse primer 
  RIG-I  Retinoic acid inducible gene I 
 RIP  Receptor interacting protein/serine-threonine kinase 1 
RLH  RIG-I like helicase 
  RLR  RIG-I like receptor 
  RMS  Root mean square 
 ROS  Reactive oxygen species  
 RVL  Rabies virus leader 
  s   sense strand 
  SAD  Single-wavelength anomalous dispersion 
SAP130  Histone deacetylase complex subunit - Sin3-associated polypeptide p130 
SDS  Sodium dodecyl sulfate  
 SEC  Size exclusion chromatography - gelfiltration 
SINTBAD  Similar to NAP1 TBK1 adaptor 
 SIRAS  Single isomorphous replacement with anomalous scattering 
TAE  Tris acedic acid EDTA 
 TANK  TRAF family member-associated NF-κB activator 
TB  Tris borate 
  TBK  TANK-binding kinase 1 
 TCEP  Tris(2-carboxyethyl)phosphine 
TEA  Triethylamin 
  TGS  TRIS Glycine SDS 
  TLR  Toll-like receptor 
  TRADD  Tumor necrosis factor receptor type 1-associated DEATH domain protein 
TRAF  TNF Receptor associated factor 
TRIM  Tripartite motif-containing 
 TRIS  Tris(hydroxymethyl)-aminomethan 
VISA  Virus-induced signaling adaptor 
wt  wildtype 
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